Compounds and methods for EMR2 modulation
Genetically modified cells using EMR2-targeting gRNAs and CRISPR/Cas nucleases address the 'on-target-off-disease' effects of immunotherapies by reducing EMR2 expression, ensuring therapeutic efficacy without harmful side effects.
Patent Information
- Application Number
- JP2024527314
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-09
- Filing Date
- 2022-11-09
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing immunotherapies, such as CAR-T therapy, often target diseased cells but also deplete non-pathological cells expressing the target antigen, leading to severe side effects and reduced efficacy due to 'on-target-off-disease' effects and fratricide, particularly when targeting antigens on immune effector cells.
Development of guide RNAs (gRNAs) that target specific domains in the EMR2 gene, combined with CRISPR/Cas nucleases, to genetically modify cells, reducing or eliminating EMR2 expression, making them resistant to immunotherapeutic agents and minimizing off-target cytotoxicity.
Genetically engineered cells with reduced EMR2 expression or expression of variant forms evade immunotherapy, maintaining their functionality while avoiding cytotoxicity, enabling safe and effective immunotherapy administration.
Smart Images

Figure 2024543369000001_ABST
Abstract
Description
[Background technology]
[0001] Related Applications This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 63 / 277,542, filed November 9, 2021, which is incorporated by reference in its entirety.
[0002] When a subject is administered an immunotherapy that targets an antigen associated with a disease or condition, e.g., an anti-cancer CAR-T therapy, the therapy may deplete not only the diseased cells that are intended to be targeted, but also non-disease cells that may express the target antigen. This "on-target, off-disease" effect has been reported for some CAR-T therapeutics, e.g., those that target CD19 or CD33. If the target antigen is expressed on the surface of cells that are required for the subject's survival, or on the surface of cells whose depletion is significantly detrimental to the subject's health, the subject will not be able to receive the immunotherapy or will face severe side effects once such a therapy is administered. In other cases, it may be desirable to administer an immunotherapy that targets an antigen expressed on the surface of immune effector cells that make up the immunotherapy, e.g., CAR-T cells, which may result in fratricide, rendering the respective therapeutic ineffective or virtually impossible to produce. Summary of the Invention
[0003] Some embodiments of the present disclosure describe compositions, methods, strategies, and treatments that address the deleterious on-target and off-disease effects of certain immunotherapeutic approaches, e.g., immunotherapeutic agents that involve lymphocytic effector cells that target specific antigens in a subject in need of treatment, such as CAR-T cells or CAR-NK cells.
[0004] An embodiment of the present disclosure provides a guide RNA (gRNA) comprising a targeting domain comprising a sequence set forth in Tables 1-8. In some embodiments, the gRNA comprises a targeting domain, and the targeting domain comprises any one of SEQ ID NOs: 59-76, 125-148, 161-166, 179, 180, 183, 184, 186, 189, 192, 195, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 249, 243, 246, 249, 252, 254-257, 268, 271, 274, 277, 280, 283, 286, 289, 291, 294, 297, 300, 303, 306, 309, 312, 315, 317, and 219. In some embodiments, the gRNA comprises a first complementarity domain, a binding domain, a second complementarity domain that is complementary to the first complementarity domain, and a proximal domain, hi some embodiments, the gRNA is a single guide RNA (sgRNA).
[0005] In some embodiments, the gRNA comprises one or more nucleotide residues that are chemically modified. In some embodiments, the gRNA comprises one or more nucleotide residues that comprise a 2'O-methyl moiety. In some embodiments, the gRNA comprises one or more nucleotide residues that comprise a phosphorothioate. In some embodiments, the gRNA comprises one or more nucleotide residues that comprise a ThioPACE moiety.
[0006] Aspects of the present disclosure provide a method of producing a genetically engineered cell, comprising providing a cell and contacting the cell with (i) any of the gRNAs described herein, or a gRNA that targets a targeting domain targeted by any of the gRNAs described herein, and (ii) an RNA-guided nuclease that binds to the gRNA, thus forming a ribonucleoprotein (RNP) complex under conditions suitable for the gRNA of (i) to form and / or maintain a ribonucleoprotein (RNP) complex with the RNA-guided nuclease of (ii) and for the RNP complex to bind to a target domain in the genome of the cell. In some embodiments, the contacting comprises introducing (i) and (ii) into the cell in the form of a preformed ribonucleoprotein (RNP) complex. In some embodiments, the contacting comprises introducing (i) and / or (ii) into the cell in the form of a nucleic acid encoding the gRNA of (i) and / or the RNA-guided nuclease of (ii). In some embodiments, the nucleic acid encoding the (i) gRNA and / or (ii) RNA-guided nuclease is RNA, preferably an mRNA or an mRNA analog. In some embodiments, the ribonucleoprotein complex is introduced into the cell via electroporation.
[0007] In some embodiments, the RNA-guided nuclease is a CRISPR / Cas nuclease. In some embodiments, the CRISPR / Cas nuclease is a Cas9 nuclease. In some embodiments, the CRISPR / Cas nuclease is a Streptococcus pyogenes Cas (spCas) nuclease. In some embodiments, the Cas nuclease is a Staphylococcus aureus Cas (saCas nuclease). In some embodiments, the CRISPR / Cas nuclease is a Cpf1 nuclease.
[0008] In some embodiments, the CRISPR / Cas nuclease comprises a mutation that reduces or eliminates nuclease activity, e.g., in some embodiments, the CRISPR / Cas nuclease is a nicase or nuclease-dead CRISPR / Cas nuclease variant.
[0009] In some embodiments, the CRISPR / Cas nuclease is fused to an endonuclease domain, e.g., a Fok-I nuclease domain. In some embodiments, the CRISPR / Cas nuclease is fused to a deamination domain, e.g., an APOBEC1 or APOBEC3 deamination domain.
[0010] In some embodiments, the CRISPR / Cas nuclease is a base editor. In some embodiments, the CRISPR / Cas nuclease is a cytosine base editor. In some embodiments, the CRISPR / Cas nuclease is an adenine base editor.
[0011] In some embodiments, the cell is a hematopoietic cell. In some embodiments, the cell is a hematopoietic stem cell. In some embodiments, the cell is a hematopoietic progenitor cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a lymphocyte. In some embodiments, the cell is a T lymphocyte.
[0012] Aspects of the present disclosure provide a genetically engineered cell obtained by any of the methods described herein. Aspects of the present disclosure provide a cell population comprising the genetically engineered cells described herein.
[0013] Aspects of the present disclosure provide cell populations comprising engineered cells, the engineered cells comprising a genomic modification consisting of an insertion or deletion immediately proximal to a site cleaved by an RNA-guided nuclease when bound to a gRNA comprising a targeting domain as set forth in Tables 1-8. In some embodiments, wherein the genomic modification is an insertion or deletion generated by a non-homologous end joining (NHEJ) event. In some embodiments, wherein the genomic modification is an insertion or deletion generated by a homology-directed repair (HDR) event. In some embodiments, the genomic modification results in a loss of function of EMR2 in engineered cells bearing such genomic modification. In some embodiments, the genomic modification results in a reduction in expression of EMR2 to less than 25%, less than 20%, less than 10%, less than 5%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, or less than 0.001% compared to the expression level of EMR2 in a wild type cell of the same cell type not bearing the EMR2 genomic modification. In some embodiments, the engineered cells are hematopoietic stem cells or hematopoietic progenitor cells.
[0014] In some embodiments, the engineered cell is an immune effector cell. In some embodiments, the engineered cell is a T lymphocyte. In some embodiments, the immune effector cell expresses a chimeric antigen receptor (CAR). In some embodiments, the CAR targets EMR2.
[0015] In some embodiments, the cell population is characterized by its ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of the recipient and generate differentiated progeny of all blood lineage cell types in the recipient. In some embodiments, the cell population is characterized by its ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of the recipient with at least 50% efficiency. In some embodiments, the cell population is characterized by its ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of the recipient with at least 60% efficiency. In some embodiments, the cell population is characterized by its ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of the recipient with at least 70% efficiency. In some embodiments, the cell population is characterized by its ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of the recipient with at least 80% efficiency. In some embodiments, the cell population is characterized by its ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of the recipient with at least 90% efficiency. In some embodiments, the cell population comprises EMR2-edited hematopoietic stem cells characterized by a differentiation potential that is equivalent to that of unedited hematopoietic stem cells.
[0016] Aspects of the disclosure provide methods comprising administering any of the genetically engineered cells described herein or any of the cell populations described herein to a subject in need thereof. In some embodiments, the subject has or has been diagnosed with a hematopoietic malignancy. In some embodiments, the method further comprises administering to the subject an effective amount of an agent that targets EMR2, where the agent comprises an antigen-binding fragment that binds to EMR2.
[0017] The above summary is intended to describe in a non-limiting manner some of the embodiments, advantages, features, and uses of the technology disclosed herein. Other embodiments, advantages, features, and uses of the technology disclosed herein will be apparent from the detailed description, drawings, examples, and claims. [Brief description of the drawings]
[0018] [Figure 1AB]Figures 1A-1E show the expression of cell surface markers CD33, CLL-1, CD123, and EMR2 on cells from patients with acute myeloid leukemia. Figure 1A shows progenitor positive cells expressing the indicated markers in blast cells (CD45dim). Figure 1B shows antigen density as measured by bound antibody per cell (blast cells). [Figure 1C-D] Figure 1C shows progenitor positive cells expressing the indicated markers in leukemia stem cells (LSC; CD45dim, CD34+, CD38-). Figure 1D shows antigen density per cell (LSC) as measured by bound antibodies for CD33, CLL-1, CD123, and EMR2 in LSCs of AML patients. [Figure 1E] Figure 1E shows the expression of the indicated markers in bone marrow and Leuko Pak samples: hematopoietic stem cells (HSC), multipotent progenitor (MPP) cells, common myeloid progenitor (CMP) cells, granulocyte-macrophage progenitor (GMP) cells, megakaryocyte-erythroid progenitor (MEP) cells, and common lymphoid progenitor (CLP) cells. For each of Figures 1A-1D, the mean (percent positive or antigen density) for each marker is shown in the table below the graphs.
[0019] [Figure 2A] Figures 2A-2E show an overview of an exemplary CRISPR strategy for EMR2 editing using an exemplary EMR2 gRNA that results in an insertion / deletion (indel) leading to a premature stop codon. Figure 2A shows the exemplary EMR2 gRNA, average editing efficiency and major indels generated in HL-60 or CD34+ cells. [Figure 2B] FIG. 2B shows the exemplary EMR2 gRNAs generated, the average editing efficiency, and major insertions / deletions (indels). [Figure 2C] Figure 2C shows the wild-type genomic and amino acid sequence regions of EMR2. The position of the guide EMR2-11 is indicated, and the four nucleotides deleted in the (-4) indel of EMR2-11 are shown between the vertical lines. [Figure 2D]FIG. 2D shows the region of the genomic and amino acid sequence of EMR2 that was edited with guide EMR2-11, which creates a deletion at −4 that results in a premature stop codon (indicated with an “*”). [Figure 2E] Figure 2E shows the wild-type genomic and amino acid sequence regions of EMR2. The position of guide EMR2-11 is indicated, and the nucleotide at the position of the (+1) indel in EMR2-11 is indicated by a vertical line. [Figure 2F] FIG. 2F shows the region of the genomic and amino acid sequence of EMR2 that was edited with guide EMR2-11, which results in a +1 insertion that results in a premature stop codon (indicated with an "*").
[0020] [Diagram 3] Figures 3A and 3B show the loss of surface expression of EMR2 after electroporation with ribonucleoprotein complexes containing Cas9 and EMR2 targeting gRNA EMR2-11 or EMR2-18. Figure 3A shows EMR2 RNA transcript expression in HL-60 cells 48 and 96 hours after electroporation. For each time point, the bars refer from left to right to WT cells, cells edited with guide EMR2-11, and cells edited with guide EMR2-18. Figure 3B shows EMR2 surface expression as a percentage of EMR2 positive live cells 48 and 96 hours after electroporation (2 and 4 days, respectively), as assessed by flow cytometry.
[0021] [Figure 4]Figures 4A and 4B show the effect of CRISPR editing with the indicated gRNAs targeting EMR2. Figure 4A shows cell number and viability 24 hours, 48 hours, 9 days, and 16 days after electroporation with RNPs containing the indicated gRNAs or mock electroporation ("Mock"). Figure 4B shows the editing efficiency of the indicated gRNAs targeting EMR2 compared to CD33 gRNA, control gRNA (gControl), or mock electroporation 48 hours, 9 days, or 16 days after electroporation, as well as the major indels observed.
[0022] [Figure 5A] Figures 5A-5C show insertion / deletion (indel) spectra and editing efficiencies for genome editing of cells with the indicated EMR2 gRNA 2 days (upper panel), 9 days (middle panel), and 16 days (lower panel) after electroporation with a ribonucleoprotein containing Cas9 and the indicated gRNA. Figure 5A shows editing with a gRNA targeting CD33 (CD33gRNA). [Figure 5B] Figure 5B shows editing with gRNA EMR2-11. [Figure 5C] Figure 5B shows editing with gRNA EMR2-18.
[0023] [Figure 6AB] Figures 6A-6G show surface expression of cell markers following electroporation with ribonucleoprotein complexes containing Cas9 and EMR2 targeting gRNA EMR2-11 or EMR2-18, CD33 gRNA, control gRNA (gCtrl), or mock electroporation ("Mock") over time. Figure 6A shows EMR2 surface expression presented as parental EMR2+ frequency. Figure 6B shows EMR2 surface expression expressed as fold change relative to cells electroporated with control gRNA (gCtrl). [Figure 6C-D]Figure 6C shows CD97 surface expression shown as parental frequency, and Figure 6D shows CD33 surface expression shown as parental frequency. [Figure 6EF] Figure 6E shows CD11b surface expression shown as parental frequency, and Figure 6F shows CD14 surface expression shown as parental frequency. [Figure 6G] FIG. 6G shows CD15 surface expression presented as parental frequency.
[0024] [Figure 7A] Figures 7A-7F show cytokine levels from in vitro differentiated CD34+ cells following electroporation with ribonucleoprotein complexes containing Cas9 and EMR2-11 or EMR2-18 targeting EMR2, control gRNA (gCtrl), or mock electroporation ("Mock EP") and stimulation with lipopolysaccharide (LPS), anti-EMR2 monoclonal antibody 2A1 (2A1), standard IgG1, or unstimulated. Figure 7A shows IFNγ levels. [Figure 7BC] Figure 7B shows IL-1β levels, and Figure 7C shows IL-6 levels. [Figure 7DE] Figure 7D shows IL-8 levels, and Figure 7E shows MIP-1α levels. [Figure 7F] FIG. 7F shows TNFα levels.
[0025] [Figure 8A] Figures 8A-8D show cell expansion and viability after electroporation with ribonucleoprotein complexes containing Cas9 and EMR2 targeting gRNA EMR2-11 or EMR2-18, guide targeting CD33 gRNA (CD33gRNA), control gRNA (gCtrl), or naive cells (Naive). Figure 8A shows the average number of viable cells cultured in granulocyte medium (myelocyte I medium) at the indicated time points after electroporation. [Figure 8BC]Figure 8B shows the percent viability of cells cultured in granulocyte medium (myelocyte I medium) at the indicated time points after electroporation, and Figure 8C shows the average number of viable cells cultured in monocyte medium (myelocyte II medium) at the indicated time points after electroporation. [Figure 8D] FIG. 8D shows the percent viability of cells cultured in granulocyte medium (myelocyte II medium) at the indicated time points after electroporation.
[0026] [Figure 9] Figure 9 shows that EMR2 editing persists throughout cell differentiation following electroporation with ribonucleoprotein complexes containing Cas9 and EMR2 targeting gRNA EMR2-11 or EMR2-18. The percentage of editing efficiency is shown over time following electroporation in differentiation medium (Mye I or Mye II).
[0027] [Figure 10] Figures 10A and 10B show surface expression of EMR2 over time following electroporation with gRNAs EMR2-11 or EMR2-18, a guide targeting CD33 (CD33gRNA), a control gRNA (Ctrl), or a ribonucleoprotein complex containing Cas9 and EMR2 targeting naive cells. Figure 10A shows EMR2 surface expression in cells cultured in granulocyte medium (myelocyte I medium) following electroporation. Figure 10B shows EMR2 surface expression in cells cultured in monocyte medium (myelocyte II medium) following electroporation.
[0028] [Figure 11AB]Figures 11A-11F show expression analysis of monocyte or granulocyte lineage markers after electroporation with gRNAs EMR2-11 or EMR2-18, guides targeting CD33 (CD33gRNA), control gRNA (Ctrl), or ribonucleoprotein complexes containing Cas9 and EMR2 targeting naive cells. Figure 11A shows expression of CD11b in granulocyte lineage cells when cultured in myeloid I medium for the indicated time points. Figure 11B shows expression of CD14 in granulocyte lineage cells when cultured in myeloid I medium for the indicated time points. [Figure 11C-D] Figure 11C shows CD11b expression in monocyte lineage cells when cultured in myeloid I medium at the indicated time points. Figure 11D shows CD14 expression in monocyte lineage cells when cultured in myeloid I medium at the indicated time points. [Fig. 11EF] Figure 11E shows CD15 expression in granulocytic lineage cells when cultured in myeloid I medium at the indicated time points. Figure 11F shows CD15 expression in monocyte lineage cells when cultured in myeloid I medium at the indicated time points.
[0029] [Figure 12AB] Figures 12A-12H show levels of cytokine production after electroporation with ribonucleoprotein complexes containing Cas9 and EMR2 targeting gRNAs EMR2-11 or EMR2-18, or control gRNA (gCtrl), and stimulation with lipopolysaccharide (LPS stim), R848 (resiquimod, R848 stim), or no stimulation at day 14 of differentiation. Figure 12A shows IL-6 levels in granulocytic lineage cells when cultured in myeloid I medium. Figure 12B shows IL-6 levels in monocyte lineage cells when cultured in myeloid II medium. [Figure 12C-D] Figure 12C shows IL-8 levels in granulocytic lineage cells when cultured in myeloid I medium. Figure 12D shows IL-8 levels in monocyte lineage cells when cultured in myeloid II medium. [Fig. 12EF]Figure 12E shows MIP-1α levels in granulocytic lineage cells when cultured in myeloid I medium, and Figure 12F shows MIP-1α levels in monocyte lineage cells when cultured in myeloid II medium. [Fig. 12GH] Figure 12G shows TNFα levels in granulocytic lineage cells when cultured in myeloid I medium, and Figure 12H shows TNFα levels in monocyte lineage cells when cultured in myeloid II medium.
[0030] [Figure 13] FIG. 13 shows a schematic of the experimental design for EMR2 guided screening and protein knockdown evaluation.
[0031] [Figure 14A] Figures 14A and 14B show expression levels of EMR2 following editing with the indicated EMR2 gRNAs 6 days after electroporation. Figure 14A shows flow cytometry analysis of EMR2 protein expression in EMR2-edited HSCs using the indicated gRNAs compared to isotype controls. [Figure 14B] FIG. 15B shows quantification of the flow cytometry data shown in FIG. 14A.
[0032] [Diagram 15AB] Figures 15A-15C show that adenosine base editing (ABE) of EMR2 using the indicated EMR2 targeting gRNAs does not affect cell viability. Figure 15A shows cell numbers measured either at day 0 (D0), day 2 (D2), and day 5 or 6 (D5 / D6) after electroporation. Figure 15B shows cell viability analysis performed either at day 0 (D0), day 2 (D2), and day 5 or 6 (D5 / D6) after electroporation. For Figures 15A and 15B, for each gRNA condition, the bars correspond, from left to right, to D0, D2, and D5 / D6, respectively. [Figure 15C]FIG. 15C is a table showing the numbers of biological replicates corresponding to the cell number and viability analyses presented in FIGS. 15A and 15B, respectively.
[0033] [Figure 16A] Figures 16A-16C show an overview of editing results in EMR2-edited cells. Figure 16A shows rhAmpSeq analysis of EMR2 editing frequency performed on day 2 (D2) and either day 5 or day 6 (D5 / D6) after electroporation. [Figure 16BC] Figure 16B shows rhAmpSeq analysis of base editing results after editing with the indicated EMR2-editing gRNAs either 2 days (D2) or 5 or 6 days (D5 / D6) after electroporation. Within each bar of the graph, the bottom corresponds to a splice site disruption, the middle portion corresponds to a missense variant, and the top corresponds to an indel in EMR2, respectively. Figure 16C is a table showing the number of biological replicates corresponding to Figures 16A and 16B.
[0034] [Diagram 17AB] Figures 17A-17C show a summary of EMR2 surface protein expression on EMR2-edited cells. Figure 17A shows flow cytometry analysis of EMR2 expression levels in EMR2-edited cells performed either on day 0 (D0), day 2 (D2), and day 5 or 6 (D5 / D6) after electroporation expressed as a percentage of EMR2 expression. Figure 17B shows geometric mean fluorescence intensity (GMFI) flow cytometry analysis of EMR2 expression in EMR2-edited cells performed either on day 0 (D0), day 2 (D2), and day 5 or 6 (D5 / D6) after electroporation expressed as geometric mean (gMFI). [Figure 17C] FIG. 17C is a table showing the number of biological replicates (n) corresponding to the flow cytometry data presented in FIGS. 17A and 17B.
[0035] [Figure 18A]Figures 18A and 18B show an overview of droplet digital PCR analysis of EMR2 transcript expression after editing with the indicated EMR2-targeting gRNA or control. Cells were harvested from experiments on the day of electroporation, 2 days (D2) or 5 days (D5) after electroporation of the indicated EMR2-targeting gRNA, control gRNA (gCrtl), or no electroporation control (no EP), and a single ddPCT reaction was performed with cDNA from all conditions at all time points. For single conditions, gRNAs were used that were ABE gRNA: EMR2-43, EMR2-62, EMR2-63, or EMR2-64. For triple conditions, the following gRNAs were used: Triple 1-EMR2-62, ABE gRNA targeting CD33, and ABE gRNA targeting CD123. Triple 2-ABE gRNA EMR2-64, ABE gRNA targeting CD33, and ABE gRNA targeting CD123. FIG. 18A shows the average normalized EMR2 transcript expression using primers for exons 19-20. [Figure 18BC] Figure 18B shows the average normalized EMR2 transcript expression using primers for exons 10 to 12. Figure 18C is a table showing the number of biological replicates (n) corresponding to the EMR transcript data presented in Figures 18A and 18B. EMR2 gRNAs EMR2-62, EMR-63, and EMR2-64 resulted in minor EMR2 transcript loss (20-50% loss compared to no EP). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0036] Some aspects of the present disclosure provide compositions, methods, strategies, and therapies relating to genetically modified cells, e.g., hematopoietic cells, that are deficient in expression of an antigen targeted by a therapeutic agent, e.g., an immunotherapeutic agent. The genetically modified cells provided herein are useful, for example, to reduce or avoid certain undesirable effects associated with certain immunotherapeutic agents, e.g., any on-target or off-disease cytotoxicity.
[0037] Such undesirable effects associated with certain immunotherapeutic agents may occur, for example, when healthy cells in a subject requiring immunotherapeutic intervention express the antigen targeted by the immunotherapeutic agent. For example, a subject may be diagnosed with a malignancy associated with an elevated level of expression of a particular antigen that is typically not expressed in healthy cells, but may be expressed at a relatively low level in a subset of non-malignant cells in the subject. Administration of an immunotherapeutic agent, such as a CAR-T cell therapy agent, or a therapeutic antibody or antibody drug conjugate (ADC) that targets the antigen to a subject may result in efficient killing of malignant cells, but may also result in the elimination of non-malignant cells that express the antigen in the subject. This on-target, off-disease cytotoxicity may result in significant side effects and, in some cases, may completely negate the use of the immunotherapeutic agent.
[0038] The compositions, methods, strategies, and treatments provided herein address the problem of on-target and off-disease cytotoxicity of certain immunotherapeutic agents. For example, some embodiments of the present disclosure provide engineered cells with modifications in their genome that result in the lack of expression of an antigen, or a specific form of that antigen, targeted by the immunotherapeutic agent. Such engineered cells, and their progeny, are not targeted by the immunotherapeutic agent and thus are not subject to any cytotoxicity brought about by the immunotherapeutic agent. For example, such cells can be administered to a subject receiving an immunotherapeutic agent that targets an antigen to replace healthy cells that may have been targeted and killed by the cellular therapy agent and / or to provide a population of cells that are resistant to targeting by the cellular therapy agent. For example, if healthy hematopoietic cells in the subject express an antigen, engineered hematopoietic cells provided herein, e.g., engineered hematopoietic stem or progenitor cells, that do not express the antigen and therefore are not targeted by the cellular therapy agent, can be administered to the subject. Such hematopoietic stem or progenitor cells can repopulate the hematopoietic niche in a subject, and their progeny can reconstitute various hematopoietic lineages, including those that would have been eliminated by the cellular therapy agent.
[0039] EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2), also called CD312, is an 823 amino acid, approximately 90 kDa protein (isoform dependent) of the EGF seven-transmembrane (TM7) family of adhesion G protein-coupled receptors (GPCRs) with a high level of homology to CD97. EMR2 forms heterodimers and binds to chondroitin sulfate B via its EGF-like domain 4, mediating cell adhesion, granulocyte chemotaxis, degranulation, and release of pro-inflammatory cytokines in macrophages. See, e.g., Kuan-Yu et al. Front. Immunol. (2017) 8:373. Without wishing to be bound by any particular theory, EMR2 is expressed on myeloid cells with highest expression in granulocytes, macrophages, and Kupffer cells.
[0040] The ADGRE2 gene, located on human chromosome 19, codes for human EMR2 and classically contains 19 exons, but due to alternative RNA splicing, there are many isoforms with different numbers of EGF domains. The dominant isoform in whole blood contains 17 exons. See, for example, Safaee et al. Onc. Rev. (2014). 8 (242): 20-24.
[0041] EMR2 expression is also associated with relapsed / refractory acute myeloid leukemia (AML). Analysis of target distribution in AML patient cells shows that EMR2 is expressed in more than 90% of AML cells (including leukemic stem cells) together with CD33, CLL1 and CD123 in most AML patients, including the majority of relapsed / refractory AML patient samples. See Figure 1A-1E.
[0042] Furthermore, aberrant EMR2 expression is associated with human breast cancer and patient survival. See, e.g., Davies et al. Oncol. Rep. (2011) 25(3):619-627. EMR2 overexpression is associated with other cancers, including bladder, colorectal, gastric and esophageal cancer, and glioblastoma. See, e.g., Safaee et al. Oncol. Rev. (2014) 8(242):20-24.
[0043] Because EMR2 is commonly expressed on antigens expressed on both activated healthy and malignant cells, therapeutic targeting of EMR2 may result in the killing of healthy cells.
[0044] Described herein are gRNAs that have been developed to specifically direct genetic modification of the gene encoding EMR2. Also provided herein are uses of such gRNAs to generate genetically modified cells, e.g., hematopoietic cells, immune cells, lymphocytes, and populations of such cells, that are deficient in EMR2 or have reduced expression of EMR2, such that the modified cells are not recognized by EMR2-specific immunotherapy. Also provided herein are methods that include administering such cells, or compositions thereof, to a subject to address the problem of on-target and off-disease cytotoxicity of certain immunotherapeutic agents. In some examples, as described herein, the genetically modified cells are hematopoietic cells that are deficient in EMR2 or have reduced expression of EMR2, for example, or that express mutants or variants of EMR2 and are therefore capable of developing into lineage-committed cells, such as T cells, that are resistant to killing by EMR2-specific immunotherapy. Alternatively or additionally, in some examples, the genetically modified cell as described herein is an immune cell, such as an EMR2-specific CAR T cell that is defective in EMR2 or has reduced expression of EMR2, or expresses a mutation or variant of EMR2 and is therefore resistant to fratricidal killing by other EMR2-specific CAR T cells. Genetically engineered cells and related compositions and methods
[0045] Some aspects of the disclosure provide engineered cells that contain a modification in their genome that results in the loss of expression of EMR2, or the expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. In some embodiments, the modification in the genome of the cells is a mutation in the genomic sequence that encodes EMR2.
[0046] The term "mutation" as used herein refers to a change in a nucleic acid sequence (e.g., an insertion, deletion, inversion, or substitution) compared to a reference sequence, e.g., a corresponding sequence in a cell that does not have such a mutation, or a corresponding wild-type nucleic acid sequence. In some embodiments provided herein, a mutation in a gene encoding EMR2 results in loss of expression of EMR2 in a cell that has the mutation. In some embodiments, a mutation in a gene encoding EMR2 results in expression of a variant form of EMR2 that is not bound by an immunotherapeutic agent that targets EMR2, or that is bound at a significantly lower level than the non-mutated EMR2 form encoded by the gene. In some embodiments, a cell that has a genomic mutation in the EMR2 gene provided herein is not bound by, or is bound at a significantly lower level by, an immunotherapeutic agent that targets EMR2, e.g., an anti-EMR2 antibody or a chimeric antigen receptor (CAR).
[0047] Some aspects of the present disclosure provide compositions and methods for generating engineered cells as described herein, for example, engineered cells that include modifications in their genome that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. Such compositions and methods provided herein include suitable strategies and approaches for engineered cells, for example, but not limited to, by using RNA-guided nucleases, such as CRISPR / Cas nucleases, and suitable RNAs that can bind such RNA-guided nucleases and target them to suitable target sites in the genome of the cell to produce genomic modifications that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2.
[0048] In some embodiments, for example, the engineered cells described herein (e.g., engineered hematopoietic cells such as engineered hematopoietic stem or progenitor cells or engineered immune effector cells) are generated via genome editing techniques, including any technique capable of introducing targeted changes, also referred to as "editing," into the genome of a cell.
[0049] One exemplary suitable genome editing technique is "gene editing," which involves the use of RNA-guided nucleases, e.g., CRISPR / Cas nucleases, to introduce targeted single- or double-stranded DNA breaks into the genome of a cell, which triggers cellular repair mechanisms such as, for example, non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ, sometimes referred to as "alternative NHEJ" or "alt-NHEJ"), or homology directed repair (HDR), which typically results in an altered nucleic acid sequence at or immediately proximal to the site of the nuclease cut (e.g., via a nucleotide or nucleotide sequence insertion, deletion, inversion, or substitution). See, e.g., Yeh et al. Nat. Cell. Biol. (2019) 21:1468-1478, e.g., Hsu et al. Cell (2014) 157:1262-1278, Jasin et al. DNA Repair (2016) 44:6-16, Sfeir et al. Trends Biochem. Sci. (2015) 40:701-714.
[0050] Another exemplary suitable genome editing technique is "base editing," which includes the use of base editors, such as nuclease-damaged or partially nuclease-damaged RNA-guided CRISPR / Cas proteins fused to deaminases that target and deaminate specific nucleobases, such as cytosine or adenosine nucleobases of C or A nucleotides, resulting in a change of a C nucleotide to a T nucleotide, or an A nucleotide to a G nucleotide, via cellular mismatch repair mechanisms. See, e.g., Komor et al. Nature (2016) 533:420-424; Rees et al. Nat. Rev. Genet. (2018) 19(12):770-788; Anzalone et al. Nat. Biotechnol. (2020) 38:824-844.
[0051] Yet another exemplary suitable genome editing technique includes "primed editing," which involves the introduction of new genetic information, e.g., modified nucleotide sequences, into specifically targeted genomic sites using catalytically impaired or partially catalytically impaired RNA-guided nucleases, e.g., CRISPR / Cas nucleases fused to engineered reverse transcriptase (RT) domains. The Cas / RT fusion is targeted to a target site in the genome by a guide RNA, which also contains a nucleic acid sequence encoding the desired edit and can function as a primer for RT. See, e.g., Anzalone et al. Nature (2019) 576(7785):149-157.
[0052] The use of genome editing technology is typically characterized by the use of a suitable RNA-guided nuclease, which in some embodiments may be catalytically impaired or partially catalytically impaired, for example, for base editing or prime editing. Examples of suitable RNA-guided nucleases include CRISPR / Cas nucleases. For example, in some embodiments, a suitable RNA-guided nuclease for use in the method of genetically engineering a cell provided herein is a Cas9 nuclease, for example, SpCas9 or SaCas9 nuclease. For another example, in some embodiments, a suitable RNA-guided nuclease for use in the method of genetically engineering a cell provided herein is a Cas12 nuclease, for example, Cas12a nuclease. Exemplary suitable Cas12 nucleases include, but are not limited to, AsCas12a, FnCas12a, other Cas12a orthologs, and Cas12a derivatives, such as the MAD7 system (MAD7™, Inscripta, Inc.), or Alt-R Cas12a (Cpf1) Ultra nuclease (Alt-R® Cas12a Ultra; Integrated DNA Technologies, Inc.). See, e.g., Gill et al. LIPSCOMB 2017. In United States: Inscripta Inc., Price et al. Biotechnol. Bioeng. (2020) 117(60):1805-1816.
[0053] In some embodiments, the engineered cells described herein (e.g., engineered hematopoietic cells, such as engineered hematopoietic stem or progenitor cells, or engineered immune effector cells) are generated by targeting an RNA-guided nuclease, such as a CRISPR / Cas nuclease, such as a Cas9 nuclease or a Cas12a nuclease, to a suitable target site in the genome of the cell under conditions suitable for the RNA-guided nuclease to bind to the target site and cleave the genomic DNA of the cell. A suitable RNA-guided nuclease can be targeted to a specific target site in the genome by a suitable guide RNA (gRNA). Suitable gRNAs for targeting CRISPR / Cas nucleases according to aspects of the present disclosure are provided herein, and exemplary suitable gRNAs are described in more detail elsewhere herein.
[0054] In some embodiments, the EMR2 gRNA described herein is complexed with a CRISPR / Cas nuclease, e.g., a Cas9 nuclease. A variety of Cas9 nucleases are suitable for use with the gRNA provided herein to effect genome editing according to aspects of the present disclosure, e.g., to generate genomic modifications in the EMR2 gene. Typically, the Cas nuclease and gRNA are provided in a form and under conditions suitable for the formation of a Cas / gRNA complex that targets a target site on the genome of a cell, e.g., a target site in the EMR2 gene. In some embodiments, a Cas nuclease is used that exhibits the desired PAM specificity to target the Cas / gRNA complex to a desired target domain in the EMR2 gene. Suitable target domains and corresponding gRNA targeting domain sequences are provided herein.
[0055] In some embodiments, the Cas / gRNA complex is formed, e.g., in vitro, and the target cell is contacted with the Cas / gRNA complex, e.g., via electroporation of the Cas / gRNA complex into the cell. In some embodiments, the cell is contacted with a Cas protein and a gRNA separately, and the Cas / gRNA complex is formed within the cell. In some embodiments, the cell is contacted with a nucleic acid, e.g., DNA or RNA, encoding a Cas protein, and / or a nucleic acid encoding a gRNA, or both.
[0056] In some embodiments, the genetically engineered cells provided herein are generated using a suitable genome editing technique, characterized by the use of a Cas9 nuclease. In some embodiments, the Cas9 molecule is of or derived from Streptococcus pyogenes (SpCas9), Staphylococcus aureus (SaCas9), or Streptococcus thermophilus (stCas9). Additional suitable Cas9 molecules include Neisseria meningitidis (NmCas9), Acidovorax avenae, Actinobacillus pleuropneumoniae, Actinobacillus succinogenes, Actinobacillus suis, Actinomyces spp., Cycliphilus denitrificans, Aminomonas paucivorans, Bacillus cereus, Bacillus smithii, Bacillus thuringiensis, Bacteroides spp., Blastopirellula marina, Bradyrhizobium spp., Brevibacillus laterosporus, Campylobacter coli, Campylobacter jejuni(CjCas9), Campylobacter lari, Candidatus puniceispirillum, Clostridium cellulolyticum, Clostridium perfringens, Corynebacterium accolens, Corynebacterium diphtheria, Corynebacterium matruchotii, Dinoroseobacter shibae, Eubacterium dolichum, gamma proteobacterium, Gluconacetobacter diazotrophicus, Haemophilus parainfluenzae, Haemophilus sputorum, Helicobacter canadensis, Helicobacter cinaedi, Helicobactermustelae, Ilyobacter polytropus, Kingella kingae, Lactobacillus crispatus, Listeria ivanovii, Listeria monocytogenes, Listeriaceae bacterium, Methylocystis spp., Methylosinus trichosporium, Mobiluncus mulieris, Neisseria bacilliformis, Neisseria cinerea, Neisseria flavescens, Neisseria lactamica, Neisseria spp., Neisseria wadsworthii, Nitrosomonas spp., Parvibaculum lavamentivorans, Pasteurella multocida, Phascolarctobacterium succinatutens, Ralstonia syzygii, Rhodopseudomonas palustris, Rhodovulum spp., Simonsiella muelleri, Sphingomonas spp., Sporolactobacillus vineae, Staphylococcus lugdunensis, Streptococcus spp., Subdoligranulum spp., Tistrella mobilis, Treponema spp., or Verminephrobacter eiseniae, or derived therefrom. In some embodiments, catalytically impaired or partially impaired variants of such Cas9 nucleases may be used. Additional suitable Cas9 nucleases and nuclease variants will be apparent to those of skill in the art based on this disclosure. The disclosure is not limited in this respect.
[0057] In some embodiments, the Cas nuclease is a naturally occurring Cas molecule. In some embodiments, the Cas nuclease is an engineered, altered, or modified Cas molecule that differs, e.g., by at least one amino acid residue, from a reference sequence, e.g., the most similar naturally occurring Cas9 molecule, or a sequence in Table 50 of PCT Publication WO2015 / 157070, which is incorporated by reference herein in its entirety.
[0058] In some embodiments, a Cas nuclease belonging to class 2 type V of Cas nucleases is used. Class 2 type V Cas nucleases can be further classified as type VA, type VB, type VC, and type VU. See, e.g., Stella et al. Nature Structural & Molecular Biology (2017). In some embodiments, the Cas nuclease is a type VB Cas endonuclease, such as C2c1. See, e.g., Shmakov et al. Mol Cell (2015) 60:385-397. In some embodiments, the Cas nuclease used in the genome editing methods provided herein is a type VA Cas endonuclease, such as Cpf1 (Cas12a) nuclease. See, e.g., Strohkendl et al. Mol. Cell (2018) 71:1-9. In some embodiments, the Cas nuclease used in the genome editing methods provided herein is a Cpf1 nuclease from Prevotella or Francisella, Acidaminococcus (AsCpf1), Lachnospiraceae (LpCpf1), or Eubacterium lectare. In some embodiments, the Cas nuclease is MAD7™ (Inscripta).
[0059] Both naturally occurring and modified variants of CRISPR / Cas nucleases are suitable for use according to aspects of the present disclosure. For example, dCas or nickase variants, Cas variants with altered PAM specificity, and Cas variants with improved nuclease activity are encompassed by some embodiments of the present disclosure. In some embodiments, the Cas nuclease is a variant with reduced PAM sequence specificity. In some embodiments, such gRNAs are referred to as "PAMless or "near PAMless". In some embodiments, the Cas nuclease is a SpRY nuclease. See, e.g., Walton et al., Science. 2020 Apr 17;368(6488):290-296, which is incorporated herein by reference.
[0060] Some features of some exemplary, non-limiting suitable Cas nucleases are described in more detail herein, without wishing to be bound by any particular theory.
[0061] Naturally occurring Cas9 nucleases typically comprise two lobes: a recognition (REC) lobe and a nuclease (NUC) lobe, each of which further comprises domains as described, for example, in PCT Publication No. WO2015 / 157070, e.g., at Figures 9A-9B therein, which application is incorporated herein by reference in its entirety.
[0062] The REC lobe comprises an arginine-rich bridge helix (BH), a REC1 domain, and a REC2 domain. The REC lobe is believed to be a Cas9-specific functional domain. The BH domain is a long alpha-helical and arginine-rich region, comprising amino acids 60-93 of the sequence of S. pyogenes Cas9. The REC1 domain is involved in the recognition of repeat:anti-repeat duplexes, for example, of gRNA or tracrRNA. The REC1 domain comprises two REC1 motifs at amino acids 94-179 and 308-717 of the sequence of S. pyogenes Cas9. These two REC1 domains are separated in the linear primary structure by the REC2 domain, but assemble in the tertiary structure to form the REC1 domain. The REC2 domain or parts thereof may also play a role in the recognition of repeat:anti-repeat duplexes. The REC2 domain comprises amino acids 180-307 of the sequence of S. pyogenes Cas9.
[0063] The NUC lobe contains a RuvC domain (also referred to herein as a RuvC-like domain), an HNH domain (also referred to herein as a HNH-like domain), and a PAM-interacting (PI) domain. The RuvC domain shares structural similarity with retroviral integrase superfamily members and cleaves single strands, e.g., non-complementary strands, of target nucleic acid molecules. The RuvC domain is constructed from three split RuvC motifs (RuvC I, RuvCII, and RuvCIII, which are often commonly referred to in the art as RuvCI domains, or N-terminal RuvC domains, RuvCII domains, and RuvCIII domains), at amino acids 1-59, 718-769, and 909-1098, respectively, of the S. pyogenes Cas9 sequence. Similar to the REC1 domain, the three RuvC motifs are linearly separated by other domains in the primary structure, but in the tertiary structure, the three RuvC motifs assemble to form the RuvC domain. The HNH domain shares structural similarity with HNH endonucleases and cleaves a single strand, e.g., the complementary strand, of a target nucleic acid molecule. The HNH domain resides between the RuvC II-III motifs and includes amino acids 775-908 of the S. pyogenes Cas9 sequence. The PI domain interacts with the PAM of the target nucleic acid molecule and includes amino acids 1099-1368 of the S. pyogenes Cas9 sequence.
[0064] Crystal structures have been determined for the naturally occurring bacterial Cas9 nuclease (see, e.g., Jinek et al., Science, 343(6176):1247997, 2014) and for S. pyogenes Cas9 with a guide RNA (e.g., a synthetic fusion of crRNA and tracrRNA) (see, Nishimasu et al., Cell (2014) 156:935-949, and Anders et al., Nature (2014) doi:10.1038 / naturel3579).
[0065] In some embodiments, the Cas9 molecules described herein exhibit nuclease activity that results in the introduction of a double-stranded DNA break at or directly proximal to the target site. In some embodiments, the Cas9 molecule is modified to inactivate one of the catalytic residues of the endonuclease. In some embodiments, the Cas9 molecule is a nickase and generates a single-stranded break. See, e.g., Dabrowska et al. Frontiers in Neuroscience (2018) 12 (75). It has been shown that one or more mutations in the RuvC and HNH catalytic domains of the enzyme can improve Cas9 efficiency. See, e.g., Sarai et al. Currently Pharma. Biotechnol. (2017) 18 (13). In some embodiments, the Cas9 molecule is fused to a second domain, e.g., a domain that modifies DNA or chromatin, e.g., a deaminase or demethylase domain. In some such embodiments, the Cas9 molecule is modified to eliminate its endonuclease activity.
[0066] In some embodiments, the Cas nucleases or Cas / gRNA complexes described herein are administered with a template for homology-directed repair (HDR). In some embodiments, the Cas nucleases or Cas / gRNA complexes described herein are administered without an HDR template.
[0067] In some embodiments, Cas9 nucleases are used that are modified to enhance the specificity of the enzyme (e.g., to reduce off-target effects and maintain robust on-target cleavage). In some embodiments, the Cas9 molecule is an enhanced specificity Cas9 variant (e.g., eSPCas9). See, e.g., Slaymaker et al. Science (2016) 351(6268):84-88. In some embodiments, the Cas9 molecule is a high fidelity Cas9 variant (e.g., SpCas9-HF1). See, e.g., Kleinstiver et al. Nature (2016) 529:490-495.
[0068] A variety of Cas nucleases are known in the art and are available from a variety of sources, and may be engineered / modified to modulate one or more activities or specificities of the enzyme. The PAM sequence preferences and specificities of suitable Cas nucleases, such as suitable Cas9 nucleases, such as SpCas9 and SaCas9, are known in the art. In some embodiments, the Cas nuclease is engineered / modified to recognize one or more PAM sequences. In some embodiments, the Cas nuclease is engineered / modified to recognize one or more PAM sequences that are different from the PAM sequence that the Cas nuclease recognizes without engineering / modification. In some embodiments, the Cas nuclease is engineered / modified to reduce the off-target activity of the enzyme.
[0069] In some embodiments, Cas nucleases are used that are further modified to alter the specificity of endonuclease activity (e.g., to reduce off-target cleavage, decrease endonuclease activity or life span in cells, increase homology-directed recombination, decrease non-homologous end joining). See, e.g., Komor et al. Cell (2017) 168:20-36. In some embodiments, Cas nucleases are used that are modified to alter the PAM recognition or preference of the endonuclease. For example, SpCas9 recognizes the PAM sequence NGG, while some variants of SpCas9 that contain one or more modifications (e.g., VQR SpCas9, EQR SpCas9, VRER SpCas9) can recognize variant PAM sequences, e.g., NGA, NGAG, and / or NGCG. As another example, SaCas9 recognizes the PAM sequence NNGRRT, whereas some variants of SaCas9 containing one or more modifications (e.g., KKH SaCas9) may recognize the PAM sequence NNRT. In another example, FnCas9 (Cas9 from Francisella novicida) recognizes the PAM sequence NNG, whereas a variant of FnCas9 containing one or more modifications (e.g., RHA FnCas9) may recognize the PAM sequence YG. In another example, a Cas12a nuclease containing substitution mutations S542R and K607R recognizes the PAM sequence TYCV. In another example, a Cpf1 endonuclease containing substitution mutations S542R, K607R, and N552R recognizes the PAM sequence TATV. See, e.g., Gao et al. Nat. Biotechnol. (2017) 35(8):789-792.
[0070] In some embodiments, more than one Cas molecule is used (e.g., two, three, or more). In some embodiments, more than one Cas9 molecule is used (e.g., two, three, or more). In some embodiments, at least one of the Cas9 molecules is a Cas9 enzyme. In some embodiments, at least one of the Cas molecules is a Cpf1 enzyme. In some embodiments, at least one of the Cas9 molecules is derived from Streptococcus pyogenes. In some embodiments, at least one of the Cas9 molecules is derived from Streptococcus pyogenes and at least one Cas9 molecule is derived from an organism that is not Streptococcus pyogenes.
[0071] In some embodiments, base editors are used to create genomic modifications that result in loss of expression of EMR2 or expression of EMR2 variants that are not targeted by immunotherapy. Base editors typically include a catalytically inactive or partially inactive Cas nuclease fused to a functional domain, e.g., a deaminase domain. See, e.g., Eid et al. Biochem. J. (2018) 475(11): 1955-1964, Rees et al. Nature Reviews Genetics (2018) 19: 770-788. In some embodiments, a catalytically inactive Cas nuclease is referred to as a "dead Cas" or "dCas". In some embodiments, a catalytically inactive Cas molecule has reduced activity, e.g., a nickase (nCas). In some embodiments, an endonuclease includes an adenine base editor (ABE), e.g., a dCas or nCas fused to an ABE evolved from the RNA adenine deaminase TadA. In some embodiments, the endonuclease comprises a cytosine base editor (CBE), e.g., a dCas or nCas fused to a CBE evolved from a cytidine deaminase enzyme (e.g., APOBEC deaminase, pmCDA1, activation-induced cytidine deaminase (AID)).
[0072] In some embodiments, the endonuclease comprises dCas9 fused to one or more uracil glycosylase inhibitor (UGI) domains. In some embodiments, the endonuclease comprises dCas9 fused to an adenine base editor (ABE), e.g., an ABE evolved from RNA adenine deaminase TadA. In some embodiments, the endonuclease comprises dCas9 fused to a cytidine deaminase enzyme (e.g., APOBEC deaminase, pmCDA1, activation-induced cytidine deaminase (AID)). In some embodiments, the catalytically inactive Cas9 molecule has reduced activity and is a Cas9 nicases (nCas9). In some embodiments, the catalytically inactive Cas9 molecule (dCas9) is fused to one or more uracil glycosylase inhibitor (UGI) domains. In some embodiments, the Cas9 molecule comprises a catalytic Cas9 molecule (dCas9) fused to an adenine base editor (ABE), e.g., an ABE evolved from RNA adenine deaminase TadA. In some embodiments, the Cas9 molecule comprises an adenine base editor (ABE), e.g., nCas9 fused to an ABE evolved from RNA adenine deaminase TadA. In some embodiments, the Cas9 molecule comprises a dCas9 fused to a cytidine deaminase enzyme (e.g., APOBEC deaminase, pmCDA1, activation-triggered cytidine deaminase (AID)). In some embodiments, the Cas9 molecule comprises an nCas9 fused to a cytidine deaminase enzyme (e.g., APOBEC deaminase, pmCDA1, activation-triggered cytidine deaminase (AID)).
[0073] Examples of suitable base editors include, but are not limited to, BE1, BE2, BE3, HF-BE3, BE4, BE4max, BE4-Gam, YE1-BE3, EE-BE3, YE2-BE3, YEE-CE3, VQR-BE3, VRER-BE3, SaBE3, SaBE4, SaBE4-Gam, Sa(KKH)-BE3, Target-AID, Target-AID-NG, xBE3, eA3A-BE3, BE-PLUS, TAM, CRISPR-X, ABE7.9, ABE7.10, ABE7.10*, ABE8, ABE8e, xABE, ABESa, VQR-ABE, VRER-ABE, Sa(KKH)-ABE, CBE, CBE1, CBE2, CBE3, CBE4, and CRISPR-SKIP. Additional examples of base editors can be found, for example, in U.S. Application Publication No. 2018 / 0312825A1, U.S. Application Publication No. 2018 / 0312828A1, and PCT Publication No. 2018 / 165629A1, which are incorporated by reference in their entireties.
[0074] Some embodiments of the present disclosure provide guide RNAs that are suitable for targeting, e.g., RNA-guided nucleases provided herein to suitable target sites within a cell's genome, to cause modifications in the cell's genome that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2.
[0075] The terms "guide RNA" and "gRNA" are used interchangeably herein and refer to a nucleic acid, typically an RNA, that is bound by an RNA-guided nuclease and facilitates specific targeting or homing of the RNA-guided nuclease to a target nucleic acid, e.g., a target site in the genome of a cell. A gRNA typically comprises at least two domains: a "binding domain," sometimes also referred to as a "gRNA scaffold" or "gRNA backbone," that mediates binding to an RNA-guided nuclease, and a "targeting domain," that mediates targeting of the gRNA-bound RNA-guided nuclease to a target site. Some gRNAs comprise additional domains, e.g., a complementarity domain, or a stem-loop domain. The structures and sequences of naturally occurring gRNA binding domains and their engineered variants are well known to those of skill in the art. Some suitable gRNAs are unimolecules that comprise a single nucleic acid sequence, while other suitable gRNAs comprise two sequences (e.g., a crRNA and a tracrRNA sequence).
[0076] Some exemplary suitable Cas9 gRNA scaffold sequences are provided herein, and additional suitable gRNA scaffold sequences will be apparent to one of skill in the art based on this disclosure. Such additional suitable scaffold sequences include, but are not limited to, those cited in Jinek, et al. Science (2012) 337(6096): 816-821, Ran, et al. Nature Protocols (2013) 8: 2281-2308, PCT Publication No. 2014 / 093694, and PCT Publication No. 2013 / 176772, which are incorporated herein by reference in their entireties.
[0077] For example, the binding domain of naturally occurring SpCas9 gRNA typically comprises two RNA molecules, crRNA (partially) and tracrRNA. Variants of SpCas9 gRNA have been engineered that comprise only a single RNA molecule, including both crRNA and tracrRNA sequences covalently linked to each other, for example, via a tetraloop or via a click chemistry type covalent bond, and are commonly referred to as "single guide RNA" or "sgRNA". Since naturally occurring Cas12a guide RNA comprises a single RNA molecule, suitable gRNAs for use with other Cas nucleases, e.g., Cas12a nuclease, typically comprise only a single RNA molecule. Thus, suitable gRNAs can be unimolecular (having a single RNA molecule), or modular (comprising more than one, typically two separate RNA molecules), sometimes referred to herein as sgRNA.
[0078] Suitable gRNAs for targeting target sites in the EMR2 gene may contain multiple domains. In some embodiments, for example, in some embodiments where Cas9 nuclease is used, the unimolecular sgRNA may comprise, from 5' to 3': a targeting domain corresponding to a target site sequence in the EMR2 gene; a first complementarity domain, Binding domains, a second complementarity domain (complementary to the first complementarity domain), The proximal domain, and Optionally, it includes a tail domain.
[0079] Each of these domains is now described in more detail.
[0080] The gRNAs provided herein typically comprise a targeting domain that binds to a target site in the genome of a cell. The target site is typically a double-stranded DNA sequence that comprises a PAM sequence and a target domain on the same strand as the PAM sequence and directly adjacent to it. The targeting domain of the gRNA typically comprises an RNA sequence that is similar to the sequence of the target domain, sometimes with one or more mismatches, but typically corresponds to the target domain sequence in that it comprises RNA instead of a DNA sequence. Thus, the targeting domain of the gRNA base pairs with the sequence of the double-stranded target site that is complementary (with full or partial complementarity) to the sequence of the target domain, and thus the strand that is complementary to the strand that comprises the PAM sequence. It will be understood that the targeting domain of the gRNA typically does not comprise a PAM sequence. It will be further understood that the location of the PAM can be 5' or 3' of the target domain sequence, depending on the nuclease employed. For example, the PAM is typically 3' of the target domain sequence for Cas9 nuclease and 5' of the target domain sequence for Cas12a nuclease. For illustrations of the location of the PAM and the mechanism of the gRNA binding to the target site, see, e.g., Figure 1 in Vanegas et al., Fungal Biol Biotechnol. (2019) 6:6, which is incorporated herein by reference. For additional illustrations and explanations of the mechanism of the gRNA targeting the RNA-guided nuclease to the target site, see Fu Y et al., Nat Biotechnol (2014) (doi:10.1038 / nbt.2808), and Sternberg SH et al., Nature (2014) (doi:10.1038 / naturel3011), both of which are incorporated herein by reference.
[0081] The targeting domain may comprise a nucleotide sequence that corresponds to the sequence of the targeting domain, i.e., the DNA sequence immediately adjacent to the PAM sequence (e.g., 5' of the PAM sequence for Cas9 nuclease, or 3' of the PAM sequence for Cas12a nuclease). The targeting domain sequence typically comprises 17-30 nucleotides and may be a perfect match to the targeting domain sequence (i.e., without any mismatched nucleotides) or may contain one or more, but typically no more than four, mismatches. Because the targeting domain is part of an RNA molecule, the DNA targeting domain will comprise deoxyribonucleotides, while the gRNA typically comprises ribonucleotides.
[0082] An exemplary illustration of a Cas9 target site comprising a 22 nucleotide targeting domain and a NGG PAM sequence, as well as a gRNA comprising a targeting domain that corresponds perfectly to the targeting domain (and thus base pairs with perfect complementarity to the DNA strand complementary to the strand containing the targeting domain and PAM) is provided below. [ka]
[0083] Exemplary illustrations of a Cas12a target site comprising a 22 nucleotide targeting domain and a TTN PAM sequence, as well as a gRNA comprising a targeting domain that corresponds perfectly to the targeting domain (and thus base pairs with perfect complementarity to a DNA strand complementary to the strand comprising the targeting domain and PAM) are provided below. [ka] In some embodiments, the Cas12a PAM sequence is 5'-TTTV-3'.
[0084] Without wishing to be bound by theory, it is believed that at least in some embodiments, the length of the targeting domain and its complementarity with the target sequence contribute to the specificity of the interaction of the gRNA / Cas9 molecular complex with the target nucleic acid. In some embodiments, the targeting domain of the gRNA provided herein is 5-50 nucleotides in length. In some embodiments, the targeting domain is 15-25 nucleotides in length. In some embodiments, the targeting domain is 18-22 nucleotides in length. In some embodiments, the targeting domain is 19-21 nucleotides in length. In some embodiments, the targeting domain is 15 nucleotides in length. In some embodiments, the targeting domain is 16 nucleotides in length. In some embodiments, the targeting domain is 17 nucleotides in length. In some embodiments, the targeting domain is 18 nucleotides in length. In some embodiments, the targeting domain is 19 nucleotides in length. In some embodiments, the targeting domain is 20 nucleotides in length. In some embodiments, the targeting domain is 21 nucleotides in length. In some embodiments, the targeting domain is 22 nucleotides in length. In some embodiments, the targeting domain is 23 nucleotides in length. In some embodiments, the targeting domain is 24 nucleotides in length. In some embodiments, the targeting domain is 25 nucleotides in length. In some embodiments, the targeting domain fully corresponds to a targeting domain sequence provided herein or a portion thereof without mismatches. In some embodiments, the targeting domain of a gRNA provided herein comprises one mismatch to a targeting domain sequence provided herein. In some embodiments, the targeting domain comprises two mismatches to a targeting domain sequence. In some embodiments, the targeting domain comprises three mismatches to a targeting domain sequence.
[0085] In some embodiments, the targeting domain comprises a core domain and a secondary targeting domain, e.g., as described in PCT Publication No. WO2015 / 157070, which is incorporated by reference in its entirety. In some embodiments, the core domain comprises about 8 to about 13 nucleotides from the 3' end of the targeting domain (e.g., the 3'-most 8 to 13 nucleotides of the targeting domain). In some embodiments, the secondary domain is positioned 5' to the core domain. In some embodiments, the core domain corresponds entirely to the targeting domain sequence or a portion thereof. In other embodiments, the core domain may comprise one or more nucleotides that are mismatched to corresponding nucleotides of the targeting domain sequence.
[0086] In some embodiments, for example, a Cas9 gRNA is provided, the gRNA comprises a first complementarity domain and a second complementarity domain, the first complementarity domain being complementary to the second complementarity domain and having sufficient complementarity to the second complementarity domain to form a double-stranded region under at least some embodiments, at least some physiological conditions. In some embodiments, the first complementarity domain is 5-30 nucleotides in length. In some embodiments, the first complementarity domain comprises three subdomains in the 5' to 3' direction: a 5' subdomain, a central subdomain, and a 3' subdomain. In some embodiments, the 5' subdomain is 4-9 nucleotides in length, e.g., 4, 5, 6, 7, 8, or 9 nucleotides in length. In some embodiments, the central subdomain is 1, 2, or 3 nucleotides in length, e.g., 1 nucleotide in length. In some embodiments, the 3' subdomain is 3-25 nucleotides in length, e.g., 4-22, 4-18, or 4-10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. The first complementarity domain can share homology with or be derived from a naturally occurring first complementarity domain. In one embodiment, it has at least 50% homology with a S. pyogenes, S. aureus, or S. thermophilus, first complementarity domain.
[0087] The sequences and arrangements of the above domains are described in more detail in PCT Publication WO2015 / 157070, which is incorporated by reference in its entirety, including pages 88-112 therein.
[0088] The binding domain may serve to link the first complementary domain of the unimolecular gRNA to the second complementary domain. The binding domain may link the first complementary domain and the second complementary domain covalently or non-covalently. In some embodiments, the linkage is a covalent bond. In some embodiments, the binding domain is or includes a covalent bond interposed between the first complementary domain and the second complementary domain. In some embodiments, the binding domain includes one or more, e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In some embodiments, the binding domain includes at least one non-nucleotide bond, e.g., as disclosed in PCT Publication No. WO2018 / 126176, the entire contents of which are incorporated herein by reference.
[0089] In some embodiments, the second complementarity domain is at least partially complementary to the first complementarity domain, and in one embodiment has sufficient complementarity to the second complementarity domain to form a double-stranded region under at least some physiological conditions. In some embodiments, the second complementarity domain can include a sequence that lacks complementarity with the first complementarity domain, e.g., a sequence that creates a loop from the double-stranded region. In some embodiments, the second complementarity domain is 5-27 nucleotides in length. In some embodiments, the second complementarity domain is longer than the first complementarity region. In one embodiment, the complementarity domain is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 nucleotides in length. In some embodiments, the second complementarity domain comprises three subdomains in the 5' to 3' direction: a 5' subdomain, a central subdomain, and a 3' subdomain. In some embodiments, the 5' subdomain is 3 to 25 nucleotides in length, e.g., 4 to 22, 4 to 18, or 4 to 10, or 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27 nucleotides in length. In some embodiments, the central subdomain is 1, 2, 3, 4, or 5 nucleotides in length, e.g., 3 nucleotides in length. In some embodiments, the 3' subdomain is 4 to 9 nucleotides in length, e.g., 4, 5, 6, 7, 8, or 9 nucleotides in length. In some embodiments, the 5' and 3' subdomains of a first complementarity domain are complementary, eg, fully complementary, to the 3' and 5' subdomains of a second complementarity domain, respectively.
[0090] In some embodiments, the proximal domain is 5-20 nucleotides in length. In some embodiments, the proximal domain may share homology with or be derived from a naturally occurring proximal domain. In one embodiment, it has at least 50% homology with a proximal domain from S. pyogenes, S. aureus, or S. thermophilus.
[0091] A wide range of tail domains are suitable for use in gRNAs. In some embodiments, the tail domain is 0 (absent), 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In some embodiments, the tail domain nucleotides are derived from or share homology with sequences from the 5' end of a naturally occurring tail domain. In some embodiments, the tail domains include sequences that are complementary to each other and form a double-stranded region under at least some physiological conditions. In some embodiments, the tail domain is absent or is 1-50 nucleotides in length. In some embodiments, the tail domain can share homology with or be derived from a naturally occurring proximal tail domain. In some embodiments, the tail domain has at least 50% homology / identity with a tail domain from S. pyogenes, S. aureus, or S. thermophilus. In some embodiments, the tail domain includes nucleotides at the 3' end that are associated with methods of in vitro or in vivo transcription.
[0092] In some embodiments, the gRNA provided herein comprises: For example, in the 5' to 3' direction, a targeting domain (corresponding to a targeting domain in the EMR2 gene), and a first strand comprising a first complementarity domain; For example, in the 5' to 3' direction, Optionally, a 5' extension domain, a second complementarity domain, The proximal domain, and and optionally a second strand comprising a tail domain.
[0093] In some embodiments, any of the gRNAs provided herein comprises one or more nucleotides that are chemically modified. Chemical modifications of gRNAs have been previously described, and suitable chemical modifications include any modifications that are beneficial for gRNA function and do not measurably increase any undesirable properties of a given gRNA, such as off-target effects. Suitable chemical modifications include, for example, those that render the gRNA less susceptible to endonuclease or exonuclease catalytic activity, including, but not limited to, phosphorothioate backbone modifications, 2'-O-Me modifications (e.g., at either or both of the 3' and 5' ends), 2'F modifications, replacement of the ribose sugar with the bicyclic nucleotide-cEt, 3'thioPACE (MSP) modifications, or any combination thereof. Additional suitable gRNA modifications will be apparent to those of skill in the art based on the present disclosure, including, but not limited to, those described in, for example, Rahdar et al. PNAS (2015) 112(51) E7110-E7117 and Hendel et al., Nat Biotechnol. (2015); 33(9): 985-989, each of which is incorporated herein by reference in its entirety.
[0094] For example, the gRNAs provided herein may comprise one or more 2'-O modified nucleotides, e.g., 2'-O-methyl nucleotides. In some embodiments, the gRNA comprises a 2'-O modified nucleotide, e.g., a 2'-O-methyl nucleotide, at the 5' end of the gRNA. In some embodiments, the gRNA comprises a 2'-O modified nucleotide, e.g., a 2'-O-methyl nucleotide, at the 3' end of the gRNA. In some embodiments, the gRNA comprises a 2'-O modified nucleotide, e.g., a 2'-O-methyl nucleotide, at both the 5' and 3' ends of the gRNA. In some embodiments, the gRNA is 2'-O modified, e.g., at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA. In some embodiments, the gRNA is 2'-O modified, e.g., the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA are 2'-O-methyl modified. In some embodiments, the gRNA is 2'-O modified, e.g., the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified, e.g., the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA. In some embodiments, the nucleotide at the 3' end of the gRNA is not chemically modified. In some embodiments, the nucleotide at the 3' end of the gRNA does not have a chemically modified sugar.In some embodiments, the gRNA is 2'-O modified, e.g., 2'-O-methyl modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA. In some embodiments, the 2'-O-methyl nucleotide comprises a phosphate linkage to the adjacent nucleotide. In some embodiments, the 2'-O-methyl nucleotide comprises a phosphorothioate linkage to the adjacent nucleotide. In some embodiments, the 2'-O-methyl nucleotide comprises a thioPACE linkage to the adjacent nucleotide.
[0095] In some embodiments, the gRNAs provided herein may comprise one or more 2'-O modified and 3' phosphorus modified nucleotides, e.g., 2'-O-methyl 3' phosphorothioate nucleotides. In some embodiments, the gRNA comprises a 2'-O modified and 3' phosphorus modified nucleotide at the 5' end of the gRNA, e.g., 2'-O-methyl 3' phosphorothioate nucleotides. In some embodiments, the gRNA comprises a 2'-O modified and 3' phosphorus modified nucleotide at the 3' end of the gRNA, e.g., 2'-O-methyl 3' phosphorothioate nucleotides. In some embodiments, the gRNA comprises a 2'-O modified and 3' phosphorus modified nucleotide at the 5' and 3' ends of the gRNA, e.g., 2'-O-methyl 3' phosphorothioate nucleotides. In some embodiments, the gRNA comprises a backbone in which one or more non-bridging oxygen atoms are replaced with a sulfur atom. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' phosphorothioate modified at the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA. In some embodiments, the nucleotide at the 3' end of the gRNA is not chemically modified.In some embodiments, the nucleotide at the 3' end of the gRNA does not have a chemically modified sugar. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, for example, 2'-O-methyl 3' phosphorothioate modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA.
[0096] In some embodiments, the gRNAs provided herein may comprise one or more 2'-O and 3'-phosphorus modifications, such as 2'-O-methyl 3'thio PACE nucleotides. In some embodiments, the gRNAs comprise a 2'-O and 3' phosphorus modification, such as 2'-O-methyl 3'thio PACE nucleotides, at the 5' end of the gRNA. In some embodiments, the gRNAs comprise a 2'-O and 3' phosphorus modification, such as 2'-O-methyl 3'thio PACE nucleotides, at the 3' end of the gRNA. In some embodiments, the gRNAs comprise a 2'-O and 3' phosphorus modification, such as 2'-O-methyl 3'thio PACE nucleotides, at the 5' and 3' ends of the gRNA. In some embodiments, the gRNAs comprise a backbone in which one or more non-bridging oxygen atoms are replaced with a sulfur atom and one or more non-bridging oxygen atoms are replaced with an acetate group. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3'thio PACE modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3'thio PACE modified at the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3'thio PACE modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' thio PACE modified at the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA. In some embodiments, the nucleotide at the 3' end of the gRNA is not chemically modified.In some embodiments, the nucleotide at the 3' end of the gRNA does not have a chemically modified sugar. In some embodiments, the gRNA is 2'-O modified and 3' phosphorus modified, e.g., 2'-O-methyl 3' thio PACE modified at the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA.
[0097] In some embodiments, the gRNA provided herein comprises a chemically modified backbone. In some embodiments, the gRNA comprises a phosphorothioate bond. In some embodiments, one or more non-bridging oxygen atoms are replaced with a sulfur atom. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a phosphorothioate bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a phosphorothioate bond.
[0098] In some embodiments, the gRNA provided herein comprises a thioPACE bond. In some embodiments, the gRNA comprises a backbone in which one or more non-bridging oxygen atoms are replaced with a sulfur atom and one or more non-bridging oxygen atoms are replaced with an acetate group. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, and the third nucleotide from the 5' end of the gRNA each comprise a thioPACE bond. In some embodiments, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a thioPACE bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end of the gRNA, the nucleotide at the 3' end of the gRNA, the second nucleotide from the 3' end of the gRNA, and the third nucleotide from the 3' end of the gRNA each comprise a thioPACE bond. In some embodiments, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a ThioPACE bond. In some embodiments, the nucleotide at the 5' end of the gRNA, the second nucleotide from the 5' end of the gRNA, the third nucleotide from the 5' end, the second nucleotide from the 3' end of the gRNA, the third nucleotide from the 3' end of the gRNA, and the fourth nucleotide from the 3' end of the gRNA each comprise a ThioPACE bond.
[0099] In some embodiments, the gRNAs described herein comprise one or more 2'-O-methyl-3'-phosphorothioate nucleotides, e.g., at least 1, 2, 3, 4, 5, or 6 2'-O-methyl-3'-phosphorothioate nucleotides. In some embodiments, the gRNAs described herein comprise modified nucleotides (e.g., 2'-O-methyl-3'-phosphorothioate nucleotides) at one or more of the three terminal positions and at the 5' terminus, and / or at one or more of the three terminal positions and at the 3' terminus. In some embodiments, the gRNAs may comprise one or more modified nucleotides, e.g., as described in PCT Publication Nos. WO2017 / 214460, WO2016 / 089433, and WO2016 / 164356, which are incorporated by reference in their entireties.
[0100] The EMR2-targeting gRNA provided herein can be delivered to cells in any suitable manner. For example, various suitable methods have been described for the delivery of CRISPR / Cas systems, including RNPs that include gRNAs bound to RNA-guided nucleases, and exemplary suitable methods include, but are not limited to, electroporation of RNPs into cells, electroporation of mRNAs and gRNAs that code for Cas nucleases into cells, various protein or nucleic acid transfection methods, and delivery of coding RNA or DNA via viral vectors, such as, for example, retroviral (e.g., lentiviral) vectors. Any suitable delivery method is encompassed by the present disclosure, which is not limited in this respect.
[0101] The present disclosure provides a number of EMR2 target sites and corresponding gRNAs that are useful for targeting RNA-guided nucleases to human EMR2. Table 1 below illustrates preferred target domains in the human endogenous EMR2 gene that can be bound by the gRNAs described herein. The exemplary target sequences of human EMR2 shown in Table 1 are, in some embodiments, for use with Cas9 nucleases, such as SpCas9. [Table 1-1] [Table 1-2]
[0102] The present disclosure provides an exemplary EMR2 targeting gRNA, which is useful for targeting RNA-guided nuclease to human EMR2.Table 2 below illustrates the preferred targeting domains for use in gRNA to target Cas9 nuclease to human endogenous EMR2 gene.The exemplary target sequence of human EMR2 shown in Table 2 is for use with Cas9 nuclease, for example, SpCas9, in some embodiments. [Table 2-1] [Table 2-2]
[0103] Exemplary base editing target site sequences of human EMR2 are provided, as well as exemplary gRNA targeting domain sequences useful for targeting such sites.For each target site, the first sequence represents the DNA targeting domain sequence, the second sequence represents its reverse complement, and the third sequence represents the exemplary targeting domain sequence of the gRNA that can be used to target each target site.The bold and underlined nucleotide residues indicate the nucleotides that are predicted to be mutated by base editors.
[0104] Exemplary target sequences for human EMR2 shown in Table 3 are, in some embodiments, for use with, for example, cytosine base editors (CBEs). [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 4]
[0105] Exemplary target sequences for human EMR2 shown in Table 5 are, in some embodiments, for use with, for example, adenine base editors (ABEs). For each target site, the first sequence represents the DNA targeting domain sequence, the second sequence represents its reverse complement, and the third sequence represents an exemplary targeting domain sequence of a gRNA that can be used to target the respective target site. [Table 5-1] [Table 5-2] [Table 5-3] [Table 6] [Table 7-1] [Table 7-2]
[0106] In some embodiments, gRNAs target most PAM sequences and have reduced PAM sequence specificity, in some embodiments, such gRNAs are referred to as "PAMless or "near PAMless." [Table 8-1] [Table 8-2] [Table 8-3]
[0107] In some embodiments, any of the gRNAs provided in Table 7 may be used with an ABE or a CBE. In some embodiments, any of the gRNAs provided in Table 7 may be used with a SpRY Cas9 with an NRN PAM.
[0108]
[0109] A representative amino acid sequence of full-length EMR2 is provided by UniProtKB / Swiss-Prot accession number Q9UHX3-1 shown below. (SEQ ID NO:167) A representative DNA sequence of EMR2 is provided by NCBI reference sequence NG_047146.1.
[0110] Some aspects of the present disclosure provide engineered cells that contain modifications in their genome that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. In some embodiments, the modification in the genome of the cell is a mutation in the genomic sequence that encodes EMR2. In some embodiments, the modification is effected through genome editing, for example, using Cas nucleases and gRNAs that target EMR2 target sites as provided herein, or including targeting domain sequences as provided herein.
[0111] While the compositions, methods, strategies, and therapeutic modalities provided herein may be applied to any cell or cell type, some exemplary cells and cell types that are particularly suitable for genomic modification in the EMR2 gene according to aspects of the present invention are described in more detail herein. Those of skill in the art will recognize, however, that the provision of such examples is for purposes of illustrating some specific embodiments, and that additional suitable cells and cell types will be apparent to those of skill in the art based on the present disclosure, and are not limited in this respect.
[0112] Some aspects of the disclosure provide engineered hematopoietic cells that contain modifications in their genome that result in loss of expression of EMR2, or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. In some embodiments, the engineered cells that contain modifications in their genome result in reduced cell surface expression of EMR2 and / or reduced binding by immunotherapeutic agents that target EMR2, for example, compared to hematopoietic cells of the same cell type but that do not contain the genomic modification. In some embodiments, the hematopoietic cells are hematopoietic stem cells (HSCs). In some embodiments, the hematopoietic cells are hematopoietic progenitor cells (HPCs). In some embodiments, the hematopoietic cells are hematopoietic stem or progenitor cells.
[0113] In some embodiments, the cell is CD34+. In some embodiments, the cell is a hematopoietic cell. In some embodiments, the cell is a hematopoietic stem cell. In some embodiments, the cell is a hematopoietic progenitor cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a lymphocyte. In some embodiments, the cell is a T lymphocyte. In some embodiments, the cell is a NK cell. In some embodiments, the cell is a stem cell. In some embodiments, the stem cell is selected from the group consisting of embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells, or tissue-specific stem cells.
[0114] In some embodiments, the cells are included in a population of cells characterized by the ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of a recipient and generate differentiated progeny of all blood lineage cell types in the recipient. In some embodiments, the cell population is characterized by the ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of a recipient with at least 50% efficiency. In some embodiments, the cell population is characterized by the ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of a recipient with at least 60% efficiency. In some embodiments, the cell population is characterized by the ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of a recipient with at least 70% efficiency. In some embodiments, the cell population is characterized by the ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of a recipient with at least 80% efficiency. In some embodiments, the cell population is characterized by the ability to engraft EMR2-edited hematopoietic stem cells in the bone marrow of a recipient with at least 90% efficiency. In some embodiments, the cell population comprises EMR2-edited hematopoietic stem cells characterized by a differentiation potential that is equivalent to that of unedited hematopoietic stem cells.
[0115] In some embodiments, hematopoietic cells (e.g., HSCs or HPCs) that contain modifications in their genome that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2 are generated using nucleases and / or gRNAs targeting human EMR2 as described herein. It will be understood that such cells can be generated by contacting cells with nucleases and / or gRNAs, or the cells can be daughter cells of cells that have been contacted with nucleases and / or gRNAs. In some embodiments, the cells described herein (e.g., genetically engineered HSCs or HPCs) are capable of populating the HSC or HPC niche and / or reconstituting the hematopoietic system of a subject. In some embodiments, the cells described herein (e.g., HSCs or HPCs) are capable of one or more (e.g., all) of engrafting a human subject, producing myeloid lineage cells, and producing lymphoid lineage cells. In some preferred embodiments, the genetically engineered hematopoietic cells provided herein, or their progeny, are preferably capable of differentiating into all blood cell lineages without any differentiation bias compared to hematopoietic cells of the same cell type, but do not contain genomic modifications that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2.
[0116] It will be appreciated that when donor cells are engrafted into a recipient host organism, for example, the relative levels of engrafted donor cells (and their progeny) and host cells in a given niche (e.g., bone marrow) are important to the physiological and / or therapeutic outcome of the host organism. The level of engrafted donor cells or their progeny relative to host cells in a given tissue or niche is referred to herein as chimerism. In some embodiments, the cells (e.g., HSCs or HPCs) described herein are capable of engrafting into a human subject and do not show any difference in chimerism compared to hematopoietic cells of the same cell type but that do not contain a genomic modification that results in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. In some embodiments, the cells described herein (e.g., HSCs or HPCs) are capable of engrafting in a human subject and exhibit no more than a 1, 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50% difference in chimerism compared to hematopoietic cells of the same cell type but that do not contain a genomic modification that results in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by an immunotherapeutic agent that targets EMR2.
[0117] In some embodiments, the genetically engineered cells provided herein contain only one genomic modification, such as a genomic modification that results in the loss of expression of EMR2 or the expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. It will be understood that the gene editing methods provided herein may result in a genomic modification in one or both alleles of a target gene. In some embodiments, genetically engineered cells that contain genomic modifications in both alleles of a given locus are preferred.
[0118] In some embodiments, the genetically engineered cells provided herein contain more than one genomic modification, e.g., one or more genomic modifications, in addition to a genomic modification that results in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by an immunotherapeutic agent that targets EMR2.
[0119] In some embodiments, the engineered cells provided herein comprise a genomic modification that results in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2, and further comprise an expression construct encoding a chimeric antigen receptor, e.g., in the form of an expression construct encoding a CAR integrated into the genome of the cell. In some embodiments, the CAR comprises a binding domain, e.g., an antibody fragment, that binds to EMR2.
[0120] Some aspects of the present disclosure provide engineered immune effector cells that contain modifications in their genome that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2. In some embodiments, the immune effector cells are lymphocytes. In some embodiments, the immune effector cells are T lymphocytes. In some embodiments, the T lymphocytes are alpha / beta T lymphocytes. In some embodiments, the T lymphocytes are gamma / delta T lymphocytes. In some embodiments, the immune effector cells are natural killer T (NKT cells). In some embodiments, the immune effector cells are natural killer (NK) cells. In some embodiments, the immune effector cells do not express an endogenous transgene, e.g., a transgenic protein. In some embodiments, the immune effector cells express a chimeric antigen receptor (CAR). In some embodiments, the immune effector cells express a CAR that targets EMR2. In some embodiments, the immune effector cells do not express a CAR that targets EMR2.
[0121] In some embodiments, the genetically engineered cells provided herein comprise a genomic modification that results in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by an immunotherapeutic agent that targets EMR2, and do not contain an expression construct encoding an exogenous protein, e.g., do not contain an expression construct encoding a CAR.
[0122] In some embodiments, the engineered cells provided herein do not substantially express EMR2 protein, e.g., do not express EMR2 protein that can be measured by a suitable method, such as immunostaining. In some embodiments, the engineered cells provided herein do not substantially express wild-type EMR2 protein, but express a mutant EMR2 protein variant, e.g., a variant that is not recognized by an immunotherapeutic agent that targets EMR2, e.g., a CAR-T cell therapeutic agent, or an anti-EMR2 antibody, antibody fragment, or antibody drug conjugate (ADC).
[0123] In some embodiments, the genetically engineered cells provided herein are hematopoietic cells, e.g., hematopoietic stem cells, hematopoietic progenitor cells (HPCs), hematopoietic stem or progenitor cells, where hematopoietic stem cells (HSCs) are cells characterized by pluripotency, self-renewal, and / or the ability to generate and / or reconstitute all lineages of the hematopoietic system, including both myeloid and lymphoid progenitor cells, which further give rise to myeloid cells (e.g., monocytes, macrophages, neutrophils, basophils, dendritic cells, erythrocytes, platelets, etc.) and lymphoid cells (e.g., T cells, B cells, NK cells), respectively. HSCs are characterized by the expression of one or more cell surface markers, e.g., CD34 (e.g., CD34+), and the absence of cell surface markers associated with lineage commitment, which can be used to identify and / or isolate HSCs. In some embodiments, the genetically engineered cells described herein (e.g., genetically engineered HSCs) do not express, express reduced amounts of, one or more cell surface markers typically associated with HSC identification or isolation, or express variant cell surface markers that are not recognized by immunotherapeutic agents that target the cell surface markers, yet are capable of self-renewal and can generate and / or reconstitute all lineages of the hematopoietic system.
[0124] In some embodiments, the population of genetically engineered cells described herein comprises a plurality of genetically engineered hematopoietic stem cells. In some embodiments, the population of genetically engineered cells described herein comprises a plurality of genetically engineered hematopoietic progenitor cells. In some embodiments, the population of genetically engineered cells described herein comprises a plurality of genetically engineered hematopoietic stem cells and a plurality of genetically engineered hematopoietic progenitor cells.
[0125] In some embodiments, the genetically engineered HSCs are obtained from a subject, such as a human subject. Methods for obtaining HSCs are described, for example, in PCT Publication No. US2016 / 057339, which is incorporated herein by reference in its entirety. In some embodiments, the HSCs are peripheral blood HSCs. In some embodiments, the mammalian subject is a non-human primate, rodent (e.g., mouse or rat), bovine, porcine, equine, or livestock. In some embodiments, the HSCs are obtained from a human subject, such as a human subject with a hematopoietic malignancy. In some embodiments, the HSCs are obtained from a healthy donor. In some embodiments, the HSCs are obtained from a subject to whom immune cells expressing a chimeric receptor are subsequently administered. HSCs administered to the same subject from whom the cells were obtained are referred to as autologous cells, whereas HSCs obtained from a subject other than the subject to whom the cells are administered are referred to as allogeneic cells.
[0126] In some embodiments, the population of genetically engineered cells is a heterogeneous population of cells, for example, a heterogeneous population of genetically engineered cells that contain different EMR2 mutations. In some embodiments, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the copies of the gene encoding EMR2 in the population of genetically engineered cells contain mutations generated by the genome editing approach described herein, for example, by the CRISPR / Cas system using gRNAs provided herein. As an example, the population of genetically engineered cells can contain multiple different EMR2 mutations, and each of the multiple mutations can contribute to the percentage of copies of EMR2 in the population of cells that have the mutation.
[0127] In some embodiments, expression of EMR2 on the genetically engineered hematopoietic cells is compared to expression of EMR2 on naturally occurring hematopoietic cells (e.g., wild-type counterparts). In some embodiments, the genetic engineering results in a reduction in the expression level of EMR2 of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% compared to expression of EMR2 on naturally occurring hematopoietic cells (e.g., wild-type counterparts). For example, in some embodiments, the genetically engineered hematopoietic cells express less than 20%, less than 19%, less than 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of EMR2 compared to naturally occurring hematopoietic cells (e.g., wild-type counterparts).
[0128] In some embodiments, the genetic manipulations described herein, e.g., using gRNAs targeting EMR2 described herein, result in a reduction in the expression level of wild-type EMR2 by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, compared to the level of expression of wild-type EMR2 on a naturally occurring hematopoietic cell (e.g., a wild-type counterpart). For example, in some embodiments, the genetically engineered hematopoietic cells express less than 20%, less than 19%, less than 18%, less than 17%, less than 16%, less than 15%, less than 14%, less than 13%, less than 12%, less than 11%, less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of EMR2 compared to naturally occurring hematopoietic cells (e.g., wild-type counterparts).
[0129] In some embodiments, the genetic engineering described herein, for example using a gRNA targeting EMR2 described herein, results in a reduction in the expression level of a wild-type lineage-specific cell surface antigen (e.g., EMR2) by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% compared to a suitable control (e.g., a cell or multiple cells). In some embodiments, a suitable control includes the level of a wild-type lineage-specific cell surface antigen measured or predicted in multiple unmanipulated cells from the same subject. In some embodiments, a suitable control includes the level of a wild-type lineage-specific cell surface antigen measured or predicted in multiple cells from a healthy subject. In some embodiments, a suitable control includes the level of a wild-type lineage-specific cell surface antigen measured or predicted in a population of cells from a pool of healthy individuals (e.g., 10, 20, 50, or 100 individuals). In some embodiments, a suitable control includes the level of wild-type lineage-specific cell surface antigen measured or predicted in a subject in need of a treatment described herein, e.g., an anti-EMR2 therapy, e.g., the subject has cancer and the cells of the cancer express EMR2.
[0130] In some embodiments, the method of genetically engineering a cell described herein includes providing a wild-type cell, e.g., a wild-type hematopoietic stem or progenitor cell. In some embodiments, the Weyl-type cell is an unedited cell that includes (e.g., expresses) two functional copies of the gene encoding EMR2. In some embodiments, the cell includes an EMR2 gene sequence provided in NCBI Reference SEQ ID NO: NG_047146.1. In some embodiments, the cell includes an EMR2 gene sequence that encodes an EMR2 protein encoded by the sequence provided by NCBI Reference SEQ ID NO: NG_047146.1, e.g., the EMR2 gene sequence may include one or more silent mutations relative to the sequence provided in NCBI Reference SEQ ID NO: NG_047146.1. In some embodiments, the cell used in the method is a natural cell or a non-engineered cell. In some embodiments, wild-type cells express EMR2 or give rise to more differentiated cells that express EMR2 at levels similar to (or within 90%-110%, 80%-120%, 70%-130%, 60%-140%, or 50%-150%) that of a cell line that expresses EMR2.
[0131] In some embodiments, wild-type cells give rise to more differentiated cells that bind antibodies that bind EMR2 (e.g., anti-EMR2 antibodies) or that bind such antibodies at levels similar to (or within 90%-110%, 80%-120%, 70%-130%, 60%-140%, or 50%-150%) antibody binding to cell lines expressing EMR2, e.g., L1236, L428, KM-H2, and L591. Antibody binding can be measured, for example, by flow cytometry or immunohistochemistry.
[0132] Dual gRNA Compositions and Uses Thereof In some embodiments, a gRNA provided herein (e.g., a gRNA provided in any of Tables 1-8) can be used in combination with a second gRNA, e.g., to target a CRISPR / Cas nuclease to two sites in a genome. For example, in some embodiments, it may be desirable to produce hematopoietic cells that are deficient in EMR2 and a second lineage-specific cell surface antigen, e.g., CD33, CD123, CLL-1, CD19, CD30, CD5, CD6, CD7, CD38, such that the cells may be resistant to two agents: an anti-EMR2 agent and an agent that targets the second lineage-specific cell surface antigen. In some embodiments, it may be desirable to contact a cell with two different gRNAs that target different sites in EMR2, e.g., to perform two cuts and create a deletion or insertion between the two cut sites. Thus, the present disclosure provides various combinations of gRNAs and associated CRISPR systems, as well as cells made by genome editing methods using such combinations of gRNAs and associated CRISPR systems. In some embodiments, the EMR2 gRNA binds to a different nuclease than the second gRNA. For example, in some embodiments, the EMR2 gRNA may bind to Cas9 and the second gRNA may bind to Cas12a, or vice versa. For example, in some embodiments, the EMR2 gRNA may bind to a base editor (e.g., ABE, CBE) and the second gRNA may bind to another RNA-guided nuclease, or vice versa.
[0133] In some embodiments, the first gRNA is selected from the group consisting of EMR2 and EMR3. and a second gRNA targeting a lineage-specific cell surface antigen selected from the following: BCMA, CD19, CD20, CD30, ROR1, B7H6, B7H3, CD23, CD33, CD38, C-type lectin-like molecule 1, CS1, IL-5, L1-CAM, PSCA, PSMA, CD138, CD133, CD70, CD5, CD6, CD7, CD13, NKG2D, NKG2D ligand, CLEC12A, CD11, CD123, CD56, CD34, CD14, CD66b, CD41, CD61, CD62, CD235a, CD146, CD326, LMP2, CD22, CD52, CD10, CD3 / TCR, CD79 / BCR, and CD26.
[0134] In some embodiments, the first gRNA is an EMR2 gRNA provided herein (e.g., a gRNA provided in any one of Tables 1-8 or a variant thereof) and the second gRNA is a lineage-specific cell surface antigen associated with a neoplastic or malignant disease or disorder, such as a specific type of cancer, including, but not limited to, CD20, CD22 (non-Hodgkin's lymphoma, B-cell lymphoma, chronic lymphocytic leukemia (CLL)), CD52 (B-cell CLL), CD33 (acute myeloid leukemia (AML)), CD1 0 (gp100) (common (pre-B) acute lymphoblastic leukemia and malignant melanoma), CD3 / T cell receptor (TCR) (T cell lymphoma and leukemia), CD79 / B cell receptor (BCR) (B cell lymphoma and leukemia), CD26 (epithelial and lymphoid malignancies), human leukocyte antigen (HLA)-DR, HLA-DP, HLA-DQ (lymphoid malignancies), RCAS1 (gynecologic, cholangiocarcinoma, and pancreatic ductal adenocarcinoma), and prostate-specific membrane antigen.
[0135] In some embodiments, the first gRNA is an EMR2 gRNA provided herein (e.g., a gRNA provided in any one of Tables 1-8 or a variant thereof) and the second gRNA targets a lineage-specific cell surface antigen selected from the following: CD1a, CD1b, CD1c, CD1d, CD1e, CD2, CD3, CD3d, CD3e, CD3g, CD4, CD5, CD6, CD7, CD8a, CD8b, CD9, CD10, CD11a, CD11b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD16, CD16b, CD17, CD18, CD19, CD20, CD 21, CD22, CD23, CD24, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32a, CD32b, CD32c, CD33, CD34, CD35, CD36, CD37, CD38, CD39, CD40, CD41, CD42a , CD42b, CD42c, CD42d, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD5 1, CD52, CD53, CD54, CD55, CD56, CD57, CD58, CD59, CD60a, CD61, CD62E, CD62L, CD62P, CD63, CD64a, CD65, CD65s, CD66a, CD66b, CD66c, CD66F, CD6 8, CD69, CD70, CD71, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD85A, CD85C, CD85D, CD85E, CD85F, CD85G, CD85H, CD85I, CD85J, CD85K, CD86, CD87, CD88, CD89, CD90, CD91, CD92, CD93, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD101, CD102, CD1 03, CD104, CD105, CD106, CD107a, CD107b, CD108, CD109, CD110, CD111, CD112, CD113, CD114, CD115, CD116, CD117, CD118, CD119, CD120a, CD120b,<h2 style=";text-align:left;direction:ltr">CD121a、CD121b、CD121a、CD121b、CD122、CD123、CD124、CD125、CD126、CD12 7、CD129、CD130、CD131、CD132、CD133、CD134、CD135、CD136、CD137、CD138、 CD139、CD140a、CD140b、CD141、CD142、CD143、CD14、CDw145、CD146、CD147、 CD148、CD150、CD152、CD152、CD153、CD154、CD155、CD156a、CD156b、CD156c、 CD157、CD158b1、CD158b2、CD158d、CD158e1 / e2、CD158f、CD158g、CD158h、C D158i、CD158j、CD158k、CD159a、CD159c、CD160、CD161、CD163、CD164、CD165 、CD166、CD167a、CD168、CD169、CD170、CD171、CD172a、CD172b、CD172g、CD1 73、CD174、CD175、CD175s、CD176、CD177、CD178、CD179a、CD179b、CD180、CD1 81、CD182、CD183、CD184、CD185、CD186、CD191、CD192、CD193、CD194、CD195 、CD196、CD197、CDw198、CDw199、CD200、CD201、CD202b、CD203c、CD204、CD2 05、CD206、CD207、CD208、CD209、CD210a、CDw210b、CD212、CD213a1、CD213a 2、CD215、CD217、CD218a、CD218b、CD220、CD221、CD222、CD223、CD224、CD225 CD226, CD227, CD228, CD229, CD230, CD231, CD232, CD233, CD234, CD235a, CD235b, CD236, CD236R, CD238, CD239, CD240, CD241, CD242, CD243, CD244, C D245, CD246, CD247, CD248, CD249, CD252, CD253, CD254, CD256, CD257, CD258, CD261, CD262, CD263, CD264, CD265, CD266, CD267, CD268, CD269, CD270,CD272, CD272, CD273, CD274, CD275, CD276, CD277, CD278, CD279, CD280, CD281, CD282, CD283, CD284, CD286, CD288, CD289, CD290, CD292, CDw293, CD29 4, CD295, CD296, CD297, CD298, CD299, CD300a, CD300c, CD300e, CD301, CD302, CD303, CD304, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD 309, CD312, CD314, CD315, CD316, CD317, CD318, CD319, CD320, CD321, CD322, CD324, CD325, CD326, CD327, CD328, CD329, CD331, CD332, CD333, CD334, CD335, CD336, CD337, CD338, CD339, CD340, CD344, CD349, CD350, CD351, CD352, CD353, CD354, CD355, CD357, CD358, CD359, CD360, CD361, CD362 or CD363.
[0136] In some embodiments, the second gRNA is a gRNA disclosed in PCT Publication Nos. WO2017 / 066760, WO2019 / 046285, WO / 2018 / 160768, or Borot et al. PNAS (2019) 116(24):11978-11987, each of which is incorporated by reference in its entirety.
[0137] Method of administration to a subject in need thereof Some embodiments of the present disclosure provide methods comprising administering to a subject in need thereof an effective number of genetically engineered cells as described herein that contain modifications in their genome that result in loss of expression of EMR2, or expression of a variant form of EMR2 that is not recognized by immunotherapeutic agents that target EMR2.
[0138] A subject in need thereof, in some embodiments, is a subject undergoing or about to undergo immunotherapy targeting EMR2. A subject in need thereof, in some embodiments, is a subject having or diagnosed with a malignancy characterized by expression of EMR2 on malignant cells. In some embodiments, a subject having such a malignancy may be a candidate for immunotherapy targeting EMR2, but the risk of adverse on-target / off-disease effects may outweigh the expected or observed benefit to the subject. In some such embodiments, administration of the genetically engineered cells described herein results in amelioration of adverse on-target / off-disease effects, because the genetically engineered cells provided herein are not efficiently targeted by immunotherapeutic agents targeting EMR2.
[0139] In some embodiments, the malignancy is a hematological malignancy, or cancer of the blood. In some embodiments, the malignancy is a lymphoid malignancy. Generally, lymphoid malignancies are associated with inappropriate production, development, and / or function of lymphatic cells, such as T-lineage or B-lineage lymphocytes. In some embodiments, the malignancy is characterized by or associated with cells that express EMR2 on the cell surface.
[0140] As described herein, EMR2 expression has also been observed in samples from patients with acute myeloid leukemia.
[0141] In some embodiments, the malignancy is associated with abnormal T lymphocytes, such as a T lineage cancer, e.g., a T cell leukemia or a T cell lymphoma.
[0142] Examples of T-cell leukemias and T-cell lymphomas include, but are not limited to, T-lineage acute lymphoblastic leukemia (T-ALL), Hodgkin's lymphoma or non-Hodgkin's lymphoma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), large granular lymphocytic leukemia, adult T-cell leukemia / lymphoma (ATLL), T-cell prolymphocytic leukemia (T-PLL), T-cell chronic lymphocytic leukemia, T-prolymphocytic leukemia, T-cell lymphocytic leukemia, and T-cell lymphoma. In some embodiments, the malignancy includes acute myeloid leukemia, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), enteropathy-associated T-cell lymphoma, B-cell chronic lymphocytic leukemia, mantle cell lymphoma, peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma, cutaneous T-cell lymphoma, angioimmunoblastic lymphoma, anaplastic large cell lymphoma, enteropathy-type T-cell lymphoma, hepatosplenic gamma delta T-cell lymphoma, lymphoblastic lymphoma, or hairy cell leukemia. In some embodiments, the malignancy is acute myeloid leukemia.
[0143] As described herein, EMR2 expression is associated with bladder cancer, breast cancer, colorectal cancer, gastric cancer and esophageal cancer, as well as glioblastoma. See, e.g., Safaee et al. Onc. Rev. (2014) 8(242):20-24.
[0144] In some embodiments, the malignancy is associated with abnormal epithelium, eg, cancer.
[0145] Examples of cancer include, but are not limited to, adrenocortical carcinoma, adenocarcinoma, basal cell carcinoma of the skin, breast cancer, ovarian cancer, colorectal cancer, gastric and esophageal cancer, invasive ductal carcinoma, pancreatic cancer, renal cell carcinoma, and squamous cell carcinoma.
[0146] In some embodiments, the malignant tumor is a glioblastoma.
[0147] Also within the scope of the present disclosure are malignancies that are considered recurrent and / or refractory, such as recurrent or refractory carcinomas. The subject in need of administration, in some embodiments, is a subject that is undergoing or will undergo immune effector cell therapy, e.g., CAR-T cell therapy, that targets EMR2, where the immune effector cells express a CAR that targets EMR2, and where at least a subset of the immune effector cells also express EMR2 on their cell surface. As used herein, "fratricide" refers to self-killing. For example, cells of a population of cells kill or induce the killing of cells of the same population. In some embodiments, cells of the immune effector cell therapy kill or induce the killing of other cells of the immune effector cell therapy. In such embodiments, fratricide ablates a portion or the entire population of immune effector cells before a desired clinical outcome can be achieved, e.g., ablation of malignant cells that express EMR2 in the subject. In some such embodiments, using engineered immune effector cells as provided herein, for example, immune effector cells that do not express EMR2 or do not express an EMR2 variant recognized by a CAR, as immune effector cells forming the basis of immune effector cell therapy, such fratricide and associated negative effects on therapeutic outcomes can be avoided. In such embodiments, engineered immune effector cells as provided herein, for example, immune effector cells that do not express EMR2 or do not express an EMR2 variant recognized by a CAR can also be further modified to express an EMR2-targeted CAR. In some embodiments, the immune effector cells can be lymphocytes, such as T lymphocytes, such as alpha / beta T lymphocytes, gamma / delta T lymphocytes, or natural killer T cells. In some embodiments, the immune effector cells can be natural killer (NK) cells.
[0148] In some embodiments, an effective number of engineered cells as described herein that contain modifications in their genome that result in loss of expression of EMR2 or expression of a variant form of EMR2 that is not recognized by an EMR2-targeted immunotherapeutic agent are administered to a subject in need thereof, e.g., a subject that is undergoing or will undergo an EMR2-targeted immunotherapy, where the immunotherapy is associated with, or at risk of being associated with, adverse on-target, off-disease effects, e.g., in the form of cytotoxicity directed toward healthy cells in the subject that express EMR2. In some embodiments, an effective number of such engineered cells may be administered to a subject in combination with an anti-EMR2 immunotherapeutic agent.
[0149] It is understood that when agents (e.g., EMR2 modified cells and an anti-EMR2 immunotherapeutic agent) are administered in combination, the cells and agent may be administered at the same time or at different times, e.g., close in time. Further, the cells and agent may be mixed, or may be mixed in separate volumes or dosage forms. For example, in some embodiments, administration in combination includes administration during the same course of treatment, e.g., during the course of treating a subject with an anti-EMR2 immunotherapy, and the subject may be administered an effective number of engineered EMR2 modified cells simultaneously with the anti-EMR2 immunotherapy, or sequentially, e.g., before, during, or after treatment.
[0150] In some embodiments, the immunotherapeutic agents targeted to EMR2 described herein are immune cells expressing a chimeric antigen receptor comprising an antigen-binding fragment (e.g., a single chain antibody) capable of binding to EMR2. The immune cells can be, for example, T cells (e.g., CD4+ or CD8+ T cells) or NK cells.
[0151] A chimeric antigen receptor (CAR) can comprise a recombinant polypeptide comprising at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain comprising a functional signaling domain, e.g., derived from a stimulatory molecule. In some embodiments, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one co-stimulatory molecule, e.g., 4-1BB (i.e., CD137), CD27, and / or CD28, or fragments of those molecules. The extracellular antigen binding domain of the CAR can comprise an EMR2-binding antibody fragment. The antibody fragment can comprise one or more CDRs, a variable region (or a portion thereof), a constant region (or a portion thereof), or any combination of the foregoing.
[0152] Exemplary antibodies that recognize human EMR2 are provided, for example, in Chang et al. FEBS Letters. (2003) 547(1-3):145-150, Yona et al. FASEB J (2008). 22(3):741-751, and PCT Publication No. WO2017 / 087800, which are incorporated by reference herein in their entireties.
[0153] Chimeric antigen receptors (CARs) typically comprise an antigen binding domain, including, for example, an antibody fragment, fused to a CAR framework, which may include a hinge region (e.g., from CD8 or CD28), a transmembrane domain (e.g., from CD8 or CD28), one or more costimulatory domains (e.g., CD28 or 4-1BB), and a signaling domain (e.g., CD3zeta). Exemplary sequences of CAR domains and components are provided, for example, in PCT Publication No. 2019 / 178382, and in Table 9 below. [Table 9-1] [Table 9-2]
[0154] In some embodiments, the number of genetically engineered cells provided herein, e.g., HSCs, HPCs, or immune effector cells, administered to a subject in need thereof is greater than or equal to 10 6 ~10 11 However, amounts below or above this exemplary range are also within the scope of the present disclosure. For example, in some embodiments, the number of engineered cells provided herein, e.g., HSCs, HPCs, or immune effector cells, administered to a subject in need thereof is about 10 6 , about 10 7 , about 10 8 , about 10 9 , about 10 10 , or about 10 11 In some embodiments, the number of genetically engineered cells provided herein, e.g., HSCs, HPCs, or immune effector cells, administered to a subject in need thereof is 10 6 ~10 9 Within the range of 10 6 ~10 8 Within the range of 10 7 ~10 9 Within the range of 10 7 ~10 10 Within the range of 10 8 ~10 10 Within the range of 10 9 ~10 11 is within the range.
[0155] In some embodiments, the immunotherapeutic agent targeting EMR2 is an antibody-drug conjugate (ADC). An ADC can be a molecule comprising an antibody or an antigen-binding fragment thereof conjugated to a toxin or drug molecule. Binding of the antibody or fragment thereof to the corresponding antigen allows delivery of the toxin or drug molecule to a cell (e.g., a target cell) that displays the antigen on its cell surface, thereby resulting in the death of the target cell.
[0156] Suitable antibodies and antibody fragments that bind to EMR2 will be apparent to those of skill in the art and include, for example, those described in PCT Publication No. 2017 / 087800, the entire contents of which are incorporated herein by reference.
[0157] Compatible toxins or drugs for use in antibody-drug conjugates are known in the art and would be apparent to one of ordinary skill in the art. See, e.g., Peters et al. Biosci. Rep. (2015) 35(4):e00225, Beck et al. Nature Reviews Drug Discovery (2017) 16:315-337, Marin-Acevedo et al. J. Hematol. Oncol. (2018) 11:8, Elgundi et al. Advanced Drug Delivery Reviews (2017) 122:2-19. In some embodiments, the antibody-drug conjugate is belantamab mafodotin.
[0158] In some embodiments, the antibody-drug conjugate may further comprise a linker (e.g., a peptide linker, such as a cleavable linker) attaching the antibody and the drug molecule.
[0159] Examples of suitable toxins or drugs for antibody-drug conjugates include, but are not limited to, brentuximab vedotin, glembatumumab vedotin / CDX-011, depatukizumab mafodotin / ABT-414, PSMA ADC, polatuzumab vedotin / RG7596 / DCDS4501A, denintuzumab mafodotin / SGN-CD19A, AGS-16C3F, CDX-014, RG7841 / DLYE5953A, RG7882 / DMUC406A, RG7986 / DCDS0780A, SGN-LIV1A, enfortumab vedotin / ASG-22ME, AG-15ME, AGS67E, terisotuzumab vedotin / ABBV-399, ABBV-221, ABBV-085, GSK-2857916, tisotuzumab vedotin / HuMax-TF-ADC, HuMax-Axl-ADC, pinatuzumab vedotin / RG7593 / DCDT2980S, rifatuzumab vedotin / RG7599 / DNIB0600A, indusatumab vedotin / MLN-0264 / TAK-264, bundletuzumab vedotin / RG7450 / DSTP3086S, sofituzumab vedotin / RG7458 / DMUC5754A, RG7600 / DMOT4039A, RG7336 / DEDN6526A, ME1547, PF-06263507 / ADC 5T4, trastuzumab emtansine / T-DM1, mirvetuximab soravtansine / IMGN853, cortuzumab emtansine / SAR3419, naratuximab emtansine / IMGN529, indatuximab emtansine / BT-062, anetumab emtansine / BAY 94-9343, SAR408701, SAR428926, AMG 224, PCA062, HKT288, LY3076226, SAR566658, lorvotuzumab mertansine / IMGN901, cantuzumab mertansine / SB-408075, cantuzumab mertansine / IMGN242, laprituximab emtansine / IMGN289, IMGN388, bivatuzumab mertansine, AVE9633, BIIB015, MLN2704, AMG 172, AMG 595, LOP628, vadatuximab butarilin / SGN-CD33A, SGN-CD70A, SGN-CD19B, SGN-CD123A, SGN-CD352A, rovalpituzumab tesirin / SC16LD6.5, SC-002, SC-003, ADCT-301 / HuMax-TAC-PBD, ADCT-402, MEDI3726 / ADC-401, IMGN779, IMGN632, gemtuzumab ozogamicin, inotuzumab ozogamicin / CMC-544, PF-06647263, CMD-193, CMB-401, trastuzumab duocarmazine / SYD985, BMS-936561 / MDX-1203, sacituzumab gonococcal Includes the toxins and drugs contained in vitecan / IMMU-132, labetuzumab govitecan / IMMU-130, DS-8201a, U3-1402, milatuzumab doxorubicin / IMMU-110 / hLL1-DOX, BMS-986148, RC48-ADC / hertuzumab-vc-MMAE, PF-06647020, PF-06650808, PF-06664178 / RN927C, rupartumab amadotin / BAY1129980, aprtumab ixadotin / BAY1187982, ARX788, AGS62P1, XMT-1522, AbGn-107, MEDI4276, and DSTA4637S / RG7861.
[0160] In some embodiments, binding of the antibody-drug conjugate to an epitope of a cell surface lineage-specific protein can induce internalization of the antibody-drug conjugate, releasing the drug (or toxin) into the cell. In some embodiments, binding of the antibody-drug conjugate to an epitope of a cell surface lineage-specific protein can induce internalization of the toxin or drug, thereby allowing the toxin or drug to kill the cell expressing the lineage-specific protein (target cell). In some embodiments, binding of the antibody-drug conjugate to an epitope of a cell surface lineage-specific protein can induce internalization of the toxin or drug, thereby allowing the toxin or drug to modulate the activity of the cell expressing the lineage-specific protein (target cell). The type of toxin or drug used in the antibody drug conjugates described herein is not limited to any particular type.
[0161] Some of the embodiments, advantages, features, and uses of the technology disclosed herein will be more fully understood from the following examples, which are intended to illustrate some of the benefits of the disclosure and to describe specific embodiments, but are not intended to exemplify the entire scope of the disclosure and therefore do not limit the scope of the disclosure. EXAMPLES
[0162] Example 1: Gene editing of EMR2 in human cells Design of sgRNA constructs
[0163] The target domains and gRNAs shown in Tables 1-2 were designed by manual inspection of PAM sequences for applicable nucleases, e.g., Cas9, Cpf1, in close proximity to the target region, and prioritized according to predicted specificity by minimizing potential off-target sites in the human genome using online search algorithms (e.g., Benchling algorithm, Doench et al., 2016; Hsu et al., 2013). All designed synthetic sgRNAs were generated with chemically modified nucleotides at the three terminal positions at both the 5' and 3' ends. The modified nucleotides included 2'-O-methyl-3'-phosphorothioates (abbreviated as "ms"), and the ms-sgRNAs were HPLC purified.
[0164] Editing in primary human CD34+ HSCs
[0165] Screening of EMR2 gRNAs was performed using the gRNAs shown in Tables 1 and 2 in HL60 cells or CD34+ cells. CD34+ HSCs derived from mobilized peripheral blood (mPB) were thawed according to the manufacturer's instructions. To edit CD34+ HSCs, approximately 1 × 10 6HSCs were thawed and cultured in StemSpan SFEM medium supplemented with StemSpan CC110 cocktail (StemCell Technologies) for 24–48 h before electroporation with RNP. To electroporate HSCs, 1.5 × 10 5 The cells were pelleted, resuspended in 20 μL of electroporation solution, and mixed with 10 μL of Cas9 RNP.
[0166] Genomic DNA analysis
[0167] For all genomic analyses, DNA was harvested from cells, amplified with primers flanking the target region, purified, and allele modification frequencies were analyzed using Tracking of Indels by Decomposition (TIDE). Analyses were performed using reference sequences from mock-transfected samples. Parameters were set to a default maximum Indel size of 10 nucleotides, and the decomposition window was set to encompass the largest window possible with high quality traces. All TIDE analyses below a detection sensitivity of 3.5% were set to 0%.
[0168] HL60 cells or human CD34+ cells were electroporated with Cas9 protein and presented with EMR2-targeting gRNA as described above. Editing rates were determined by % indels as assessed by TIDE analysis. Editing efficiency was determined by flow cytometry analysis. See Figures 2A-2F, 4B, 5A-5C. As shown in Figures 2C-2F, we found that editing of EMR2 with guide EMR2-11 resulted in a premature stop codon, either through the deletion of four nucleotides (-4) or the addition of one nucleotide (+1).
[0169] Expression and flow cytometry analysis
[0170] EMR2 gRNA edited cells were also evaluated for expression of EMR2 RNA transcripts and surface expression of EMR2 protein, e.g., by flow cytometry analysis (FACS). To evaluate surface expression, live CD34+ HSCs were stained for EMR2 using anti-EMR2 antibody and analyzed by flow cytometry. Cells genetically modified with the EMR2 gene showed a reduction in EMR2 expression as detected by FACS. See Figures 3A and 3B.
[0171] EMR2 gRNA-edited cells were also assessed for surface expression of EMR2 protein over time in culture, which showed a significant and sustained reduction in EMR2 expression, see Figures 6A and 6B.
[0172] Surface expression of CD97 and CD33 as well as several myeloid markers (e.g., CD11b, CD14, CD15) was also assessed over time. These markers were not significantly affected by editing of EMR2. See Figures 6C-6G.
[0173]
[0174] Cytokine levels
[0175] Cytokine production was assessed for in vitro differentiated CD34+ cells following stimulation with lipopolysaccharide (LPS), anti-EMR2 antibody (2A1), or IgG1. See Figures 7A-7F. As expected, LPS simulation resulted in upregulation of pro-inflammatory cytokines compared to unstimulated cells. Regardless of editing, we did not observe a significant shift in cytokine production (i.e., IFN-γ, IL1b, IL-6, IL-8, MIP-1α, TNFα), suggesting that loss of EMR2 expression does not affect cytokine secretion. Furthermore, minimal, if any, upregulation of cytokines was observed upon stimulation with 2A1.
[0176]
[0177] Viability of edited cells
[0178] At various time points after ex vivo editing, e.g., 24 hours, 48 hours, 9 days, and 16 hours, the total number of cells and the percentage of live edited EMR2KO cells and control cells were quantified. EMR2KO cells edited using EMR2 gRNA described herein were viable and remained viable over time after electroporation and gene editing. This was similar to what was observed in the control mock-edited cells. See Figure 4A.
[0179] Example 2: Generation and evaluation of EMR2-edited cells Genetically modified cells were generated using exemplary gRNAs, EMR2-11 and EMR2-18, using cells from a single donor and analyzed for in vitro differentiation. Genome editing using a gRNA targeting CD33 (CD33gRNA) and a control gRNA (gCtrl) was also used. After genome editing, cells were cultured in either granulocytic medium (Mye I) or monocytic medium (Mye II). Cell number and cell viability were assessed at various time points after editing (post-electroporation).
[0180] As shown in Figures 8A-8D, editing of EMR2 did not affect cell expansion or viability of granulocytic or monocytic cells, with over 80% of EMR2-edited HSPCs retaining viability. High levels of EMR2 editing efficiency were also maintained throughout differentiation for all EMR2 gRNAs tested; see Figure 9. We found that editing with guide EMR2-11 resulted in loss of EMR2 surface expression by 6 days post-electroporation, which persisted for at least 12 days post-electroporation; see Figures 10A and 10B.
[0181] As observed in Example 1, editing of EMR2 did not affect expression of the monocyte markers CD11b or CD14, nor the granulocyte lineage marker CD15. See Figures 11A-11F.
[0182] Cytokine production was also assessed to determine whether EMR2 editing modulates cell function. Cells were stimulated with or without LPS or R848 and assessed for production of IL-6, IL-8, MIP-1α, and TNFα. As shown in Figures 12A-12H, EMR2 editing did not affect any of the cytokines measured, i.e., IL-6, IL-8, MIP-1α, and TNFα.
[0183] The cellular function of the EMR2 edited cells may also be assessed, for example, phagocytosis.
[0184] Example 3: Gene editing of EMR2 in human cells Design of sgRNA constructs
[0185] The target domains and gRNAs shown in Tables 3-4 were designed by manual inspection of PAM sequences for applicable nucleases, e.g., base editor nucleases, in close proximity to the target region, and prioritized according to predicted specificity by minimizing potential off-target sites in the human genome using online search algorithms (e.g., Benchling algorithm, Doench et al. 2016; Hsu et al. 2013). All designed synthetic sgRNAs were generated with chemically modified nucleotides at the three terminal positions at both the 5' and 3' ends. The modified nucleotides contained 2'-O-methyl-3'-phosphorothioates (abbreviated as "ms"), and the ms-sgRNAs were HPLC purified.
[0186] Editing in primary human CD34+ HSCs
[0187] Screening of EMR2 gRNAs was performed using the gRNAs shown in Tables 3 and 4 in HL60 cells or CD34+ cells. CD34+ HSCs derived from mobilized peripheral blood (mPB) were thawed according to the manufacturer's instructions. To edit CD34+ HSCs, approximately 1 × 106 HSCs were thawed and cultured for 24-48 hours in StemSpan SFEM medium supplemented with StemSpan CC110 cocktail (StemCell Technologies) prior to electroporation with RNP. To electroporate HSCs, 1.5 × 105 cells were pelleted, resuspended in electroporation solution, mixed with ribonucleoprotein complexes containing gRNA and nuclease, resuspended in electroporation solution, mixed with ribonucleoprotein complexes containing gRNA and nuclease.
[0188] Exemplary base editor nucleases are shown below. Amino acid sequence of an exemplary cytidine deaminase (SEQ ID NO:173) MTSEKGPSTGDPTLRRRIESWEFDVFYDPRELRKETCLLYEIKWGMSRKIWRSSGKNTTN HVEVNFIKKFTSERRFHSSISCSITWFLSWSPCWECSQAIREFLSQHPGVTLVIYVARLF WHMDQRNRQGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYAL ELHCIILSLPPCLKISRRWQNHLAFFRLHLQNCHYQTIPPHILLATGLIHPSVTWRLKSG GSSGGSSGSETPGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKK FKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMA KVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAI LSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTY DDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQD LTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLV KLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPPYY VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKH SLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKK IECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREM IEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANR NFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGQILKEHPVENTQLQNEKL YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVP SEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHV AQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNA VVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIL PKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMER SSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSK YVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVL SAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS ITGLYETRIDLSQLGGDSGGSGGSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIG NKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSGGSGGS TNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSD APEYKPWALVIQDSNGENKIKMLPKKKRKV Nucleic acid sequence of an exemplary cytidine deaminase (SEQ ID NO:174) Amino acid sequence of an exemplary adenosine deaminase (SEQ ID NO:175) MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHEI MALRQGGLVMQNYRLYDATLYSTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDV LHHPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSSTDSGGSSGGSSGSET PGTSESATPESSGGSSGGSDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHS IKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLE ESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRL ENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQI GDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQ LPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQ RTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRF AWMTRKSEETITTPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYN ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISG VEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHL FDDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSL TFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIE MARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDM YVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNY WRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTK YDENDLIREVKIVTLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYP KLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFKTEITLANGEIRKRPL IETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIAR KKDWDPKKYGGFDSPTVAYSVLVVAKVEGKGKSKKLKSVKELLGITIMERSSFEKNPIDFL EAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHY EKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPI REQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDL SQLGGDEGADKRTADGSEFESPKKKRKV Exemplary Adenosine Deaminase Nucleic Acid Sequence (SEQ ID NO:176)
[0189] For all genomic analyses, DNA is harvested from cells, amplified with primers flanking the target region, purified, and analyzed for allelic modification frequency. Editing efficiency is determined by flow cytometry analysis.
[0190] Expression and flow cytometry analysis
[0191] EMR2 gRNA edited cells may also be assessed for expression of EMR2 RNA transcripts and surface expression of EMR2 protein, for example, by flow cytometric analysis (FACS).
[0192] Expression of other surface markers such as CD97 and CD33 as well as several myeloid markers (eg, CD11b, CD14, CD15) may also be assessed over time.
[0193] Viability of edited cells
[0194] At various time points after ex vivo editing, e.g., 24 hours, 48 hours, 9 days, and 16 hours, the total number of cells and the percentage of live EMR2 and control cells are quantified.
[0195] Example 4: CAR-T cytotoxicity assay Genetically modified cells generated using the gRNAs shown in Tables 1-8 may be assessed for killing by EMR2-CAR T cells.
[0196] CAR constructs and lentivirus production
[0197] A second generation CAR is constructed to target EMR2. An exemplary CAR construct consists of an extracellular scFv antigen binding domain using CD8α signal peptide, CD8α hinge and transmembrane region, 4-1BB costimulatory domain, and CD3ζ signaling domain. Anti-EMR2 scFv sequence can be obtained from any anti-EMR2 antibody known in the art. The CAR cDNA sequence for the target is subcloned into the multiple cloning site of pCDH-EF1α-MCS-T2A-GFP expression vector, and lentivirus is generated according to the manufacturer's protocol (System Biosciences). Lentivirus can be generated by transient transfection of 293TN cells (System Biosciences) using Lipofectamine 3000 (ThermoFisher). An exemplary CAR construct is generated by cloning the light and heavy chains of an anti-EMR2 antibody into the CD8α hinge domain, ICOS transmembrane domain, ICOS signaling domain, 4-1BB signaling domain, and CD3ζ signaling domain into the lentiviral plasmid pHIV-Zsgreen.
[0198] CAR transduction and expansion
[0199] Human primary T cells are isolated from Leuko Pak (Stem Cell Technologies) by magnetic bead separation using anti-CD4 and anti-CD8 microbeads according to the manufacturer's protocol (Stem Cell Technologies). Purified CD4+ and CD8+ T cells are mixed 1:1 and activated using anti-CD3 / CD28-conjugated Dynabeads (Thermo Fisher) at a bead-to-cell ratio of 1:1. The T cell culture medium used is CTS Optimizer T cell growth medium supplemented with immune cell serum replacement, L-glutamine and GlutaMAX (all purchased from Thermo Fisher) and 100 IU / mL IL-2 (Peprotech). T cell transduction is performed 24 hours after activation by spinoculation in the presence of polybrene (Sigma). CAR-T cells are cultured for 9 days before cryopreservation. Before all experiments, T cells are thawed and rested at 37°C for 4-6 hours.
[0200] Flow cytometry-based CAR-T cytotoxicity assay
[0201] The cytotoxicity of target cells is measured by comparing the survival of target cells to the survival of negative control cells. For EMR2 cytotoxicity assay, wild type and CRISPR / Cas9 edited cells of EMR2 expressing AML cell line are used as target cells. Wild type Raji cell line (ATCC) is used as negative control for both experiments. Alternatively, CD34+ cells can be used as target cells, and CD34+ cells that are EMR2 deficient or have reduced expression of EMR2 or express variants of EMR2 can be generated as described in Examples 1-3.
[0202] Target cells and negative control cells are stained with CellTrace Violet (CTV) and CFSE (Thermo Fisher), respectively, according to the manufacturer's instructions. After staining, target cells and negative control cells are mixed 1:1.
[0203] Anti-EMR2 CAR-T cells are used as effector T cells. Non-transduced T cells (mock CAR-T) are used as control. Effector T cells are co-cultured with target cells / negative control cell mixtures in duplicate at an effector-to-target ratio of 1:1. A group of target cells / negative control cell mixtures alone without effector T cells is included as a control. Cells are incubated at 37° C. for 24 hours before flow cytometry analysis. Propidium iodide (ThermoFisher) is used as a viability dye. The fraction of live target cells relative to live negative control cells (referred to as target fraction) is used for calculation of specific cell lysis. Specific cell lysis is calculated as (target fraction without effector cells-target fraction with effector cells) / (target fraction without effector)×100%.
[0204] Example 5: Effect of anti-EMR2 antibody drug conjugates on engineered HSCs Genetically modified cells generated using the gRNAs shown in Tables 1-8 may be assessed for killing by antibody-drug conjugates, such as anti-EMR2 antibodies conjugated to immunotoxins.
[0205] Frozen CD34+ HSPCs derived from mobilized peripheral blood are thawed and cultured for 72 hours prior to electroporation with ribonucleoprotein containing Cas9 and sgRNA. Samples are electroporated under the following conditions: i. Mock (nuclease only (e.g., Cas9), and ii.KO sgRNA (such as any one of the EMR2 gRNAs shown in Tables 1-8). Cells are allowed to recover for 72 hours and genomic DNA is harvested and analyzed. The percentage of EMR2 positive cells is assessed by flow cytometry to confirm that editing with EMR2 gRNA is effective in knocking out or reducing EMR2. Editing events in HSCs result in various Indel sequences.
[0206] Sensitivity of cells with EMR2 deletion to antibody-drug conjugates
[0207] To determine in vitro toxicity, cells are incubated with the antibody-drug conjugate in culture medium and the number of viable cells is quantified over time. Engineered cells that are deficient in EMR2 or have reduced EMR2 expression generated with the EMR2 gRNA described herein are more resistant to antibody-drug conjugate treatment than cells expressing full-length EMR2 (mock).
[0208] (ii) Enrichment of EMR2-modified cells
[0209] To assay whether EMR2 modified cells are enriched after treatment with antibody drug conjugates, CD34+ HSPCs are edited with a standard nuclease (e.g., Cas9, Cpf1) to gRNA ratio of 50%. The bulk population of cells is analyzed before and after treatment with antibody drug conjugates. After treatment with antibody drug conjugates, EMR2 modified cells are enriched such that the proportion of EMR2-deficient cells increases.
[0210] (iii) In vitro differentiation of CD34+ HSPCs
[0211] The cell populations are evaluated for lymphoid differentiation before and after treatment with antibody drug conjugates at various days after differentiation. Engineered EMR2 knockout cells generated using EMR2 gRNA described herein may show increased expression of differentiation markers, whereas cells expressing full-length EMR2 (mock) may not differentiate.
[0212] Example 6: Assessment of persistence of EMR2KO CD34+ cells in vivo Editing in mobilized peripheral blood CD34+HSCs (mPB CD34+HSPCs)
[0213] gRNAs were designed as described in Examples 1 and 3. mPB CD34+ HSPCs were thawed according to the manufacturer's instructions. These cells are then edited via nucleases (e.g., CRISPR / Cas9) as described in Examples 1-3 using the EMR2-targeting gRNAs described herein, as well as a non-EMR2-targeting control gRNA (gCtrl) designed not to target any region within the human or mouse genome.
[0214] The percentage of viable edited EMR2KO and control cells is quantified using flow cytometry and 7AAD viability dye at 4, 24, and 48 hours after ex vivo editing. High levels of EMR2KO cells edited using the EMR2 gRNAs described herein are viable and can remain viable for hours after electroporation and gene editing, comparable to that observed in control cells edited with a non-EMR2 gRNA-targeted control gRNA, gCtrl.
[0215] In addition, 48 hours after ex vivo editing, genomic DNA is harvested from the cells, PCR amplified with primers flanking the targeted region, purified, and analyzed by TIDE to determine the percentage of editing as assessed by INDEL (insertion / deletion), as described in Example 1.
[0216] After TIDE analysis, the percentage of long-term HSCs (LT-HSCs) after editing with EMR2 gRNAs as described herein is quantified by flow cytometry. The percentage of LT-HSCs after editing with a specified EMR2 gRNA is evaluated. This assay can be performed upon cryopreservation of edited cells, for example, before injection into mice to investigate the persistence of EMR2KO cells in vivo. Edited cells are diluted at 5×10 in a volume of 1 mL of medium per vial. 6 Cryopreserved at cells / mL in CryoStor® CS10 medium (Stem Cell Technology).
[0217] Examination of engraftment efficiency and persistence of EMR2KO mPB CD34+ HSPCs in vivo
[0218] Female NSG mice (JAX), 6-8 weeks of age, are allowed to acclimate for 2-7 days. After acclimation, mice are irradiated using 175 cGy total body irradiation with an X-ray irradiator. This is considered day 0 of the study. 4-10 hours after irradiation, mice are engrafted with EMR2KO cells generated during any of the EMR2 gRNAs described herein or control cells edited with gCtrl. Cryopreserved cells are thawed and counted using a BioRad TC-20 automated cell counter. The number of viable cells is quantified in the thawed vial and used to prepare the total number of cells for engraftment in mice. Mice are engrafted with 1 x 10 cells in a 100 μL volume. 6 A single intravenous injection of edited cells will be given. Body weight and clinical observations will be recorded weekly for each mouse in the four groups.
[0219] At 8 and 12 weeks after engraftment, 50 μL of blood is collected from each mouse by retro-orbital bleeding for analysis by flow cytometry. At 16 weeks after engraftment, mice are sacrificed and blood, spleen, and bone marrow are collected for analysis by flow cytometry. Bone marrow is isolated from femurs and tibias. Bone marrow from femurs is also used for on-target editing analysis. Flow cytometry is performed using FACSCanto™ 10 color and BDFACSDiva™ software. Cells are typically first sorted by viability using 7AAD viability dye (live / dead analysis), and then live cells are gated by expression of human CD45 (hCD45), but not mouse CD45 (mCD45). Cells that are hCD45+ are then further gated for expression of human CD19 (hCD19) (lymphoid cells, specifically B cells). Cells expressing human CD45 (hCD45) are also gated and analyzed for the presence of various cell markers of the myeloid lineage.
[0220] The number of cells expressing each of the analyzed markers, which was comparable across all mice regardless of which edited cells were engrafted, indicates successful engraftment of EMR2 gRNA-edited EMR2KO cells in the blood of the mice.
[0221] At 8, 12, and 16 weeks post-engraftment, the percentage of nucleated blood cells that are hCD45+ is quantified in groups of mice (n=15 mice / group) that received control cells edited with control gRNA (gCtrl) or EMR2KO cells by dividing the absolute hCD45+ cell count by the absolute mouse CD45+ (mCD45) cell count.
[0222] The percentage of hEMR2+ cells in the blood will also be quantified at week 8 post-engraftment in control and EMR2KO mice. Mice engrafted with EMR2KO cells (edited with any of the EMR2 gRNAs described herein) are expected to have significantly lower levels of hEMR2+ cells compared to mice engrafted with control cells at weeks 8, 12, and 16.
[0223] Next, the percentages of specific populations of differentiated cells in the blood, such as CD19+ lymphoid cells, hCD14+ monocytes, and hCD11b+ granulocytes / neutrophils, are quantified at 8, 12, and 16 weeks post-engraftment in mice engrafted with EMR2KO or control cells. Levels of hCD19+, hCD14+, and hCD11b+ cells in the blood were comparable between the control and EMR2KO groups, and the levels of these cells remained comparable from 8 to 16 weeks post-engraftment. Comparable levels of hCD19+, hCD14+, and hCD11b+ cells in the blood indicate that similar levels of human myeloid and lymphoid cell populations are present in mice receiving EMR2KO cells and mice receiving control cells.
[0224] Finally, amplicon-seq can be performed on bone marrow samples isolated 16 weeks post-engraftment to analyze on-target EMR2 editing in mice engrafted with edited EMR2KO cells.
[0225] Evaluating cell samples obtained from the spleens of engrafted animals
[0226] At 16 weeks post-engraftment, the percentage of hCD45+ cells and the percentage of hEMR2+ cells are also quantified in the spleens of mice engrafted with control or EMR2KO cells. Comparable levels of hCD45+ cells and reduced levels of hEMR2+ cells between groups of mice (engrafted with control or EMR2KO cells) may indicate long-term persistence of EMR2KO HSCs in the spleens of NSG mice.
[0227] In addition, the percentages of hCD14+ monocytes, hCD11b+ granulocytes / neutrophils, CD19+ lymphoid cells, and hCD3+ T cells in the spleen will be quantified 16 weeks after engraftment. Comparable levels of hCD14+, hCD11b+, hCD19+, and hCD3+ cells in the spleen between control and EMR2KO groups may indicate that edited EMR2KO cells are capable of multilineage human hematopoietic cell reconstitution in the spleen of NSG mice.
[0228] Evaluate blood and bone marrow neutrophils
[0229] Sixteen weeks after engraftment, the percentage of hCD11b+ cells is quantified in the blood and bone marrow of mice engrafted with control or EMR2KO cells. Comparable levels of CD11b+ neutrophil populations were observed in both the blood and bone marrow of NSG mice engrafted with control and EMR2KO cells, indicating successful engraftment and differentiation.
[0230] Evaluate blood and bone marrow myeloid and lymphoid progenitor cells
[0231] Also, the percentage of hCD123+ cells in the blood and bone marrow, and the percentage of hCD10+ cells in the bone marrow will be quantified in mice engrafted with control or EMR2KO cells at week 16. Comparable levels of myeloid and lymphoid progenitor cells between the control and EMR2KO groups may indicate successful engraftment and development.
[0232] Example 7: Editing EMR2 using the CBE and ABE base editors A screening process was utilized to evaluate exemplary guide RNAs for editing EMR2 with CBEs and ABEs in CD34+ cells. See FIG. 13. Examples of gRNAs designed and screened for EMR2 editing efficiency when paired with base editors such as CBEs and ABEs are found in Tables 3 and 4 and Tables 5-7. A control gRNA not targeting EMR2 (gCtrl) with the sequence GCCGACGCGAAATCTTAGCG (SEQ ID NO: 320) was used in the analysis.
[0233] Viability of edited cells
[0234] At various time points after editing, cell number and cell viability analyses were performed, which showed that editing with the CBE and ABE of EMR2 did not cause a reduction in cell viability, see Figures 15A-15C.
[0235] DNA editing analysis
[0236] Analysis of EMR2 editing results using CBE and ABE in HSCs was performed using rhAmpSeq at various time points after electroporation. Results showed high levels of editing and efficient splice site disruption in EMR2. See Figures 16A-16C.
[0237] Flow cytometry analysis of EMR2 protein expression
[0238] Flow cytometry analysis of EMR2 edited cells electroporated with gRNAs and base editors revealed gRNAs that resulted in significant levels of EMR2 knockdown. See Figures 14A-14B and 17A-17C.
[0239] Transcript expression analysis
[0240] Droplet digital PCR analysis of EMR2 transcripts showed a 20-50% reduction in the levels of EMR2 mRNA transcripts compared to control cells that were not electroporated. See Figures 18A-18C.
[0241] References All publications, patents, patent applications, publications, and data base entries (e.g., sequence database entries) mentioned herein, for example in the Background, Summary, Detailed Description, Examples, and / or References sections, are incorporated herein by reference in their entirety, just as if each individual publication, patent, patent application, publication, and database entry was specifically and individually incorporated herein by reference. In the case of conflict, the present application, including any definitions herein, will control. Equivalents and Scope
[0242] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.
[0243] Articles such as "a," "an," and "the" can mean one or more than one, unless indicated to the contrary or clear from the context. A claim or specification containing "or" between two or more members of a group is deemed to be satisfied when one, more than one, or all of the members of the group are present, unless indicated to the contrary or clear from the context. The disclosure of a group containing "or" between two or more group members provides embodiments in which exactly one member of the group is present, embodiments in which two or more members of the group are present, and embodiments in which all of the members of the group are present. For the sake of brevity, these embodiments are not individually detailed herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or denied.
[0244] It should be understood that the present invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, or descriptive terms from one or more of the claims, or from one or more relevant portions of the specification, are introduced into another claim. For example, a claim that depends on another claim can be modified to include one or more of the limitations found in any other claim that depends on the same base claim. Furthermore, when a claim recites a composition, it should be understood that the claim includes a method of making or using the composition according to any of the methods of making or using disclosed herein, or according to methods known in the art, if any, unless otherwise indicated or unless a contradiction or inconsistency would arise that is obvious to one of ordinary skill in the art.
[0245] When elements are presented as a list, for example in Markush group format, it should be understood that all possible subgroups of the elements are also disclosed, and that any element or subgroup of elements can be excluded from the group. It should also be noted that the term "comprising" is intended to be open-ended, allowing for the inclusion of additional elements or steps. In general, when an embodiment, product, or method is referred to as comprising a particular element, feature, or step, it should be understood that an embodiment, product, or method consisting of or consisting essentially of such element, feature, or step is also provided. For the sake of brevity, these embodiments are not individually detailed herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or denied.
[0246] When ranges are given, the endpoints are included. Furthermore, unless otherwise indicated or clear from the context and / or understanding of one of ordinary skill in the art, it should be understood that values expressed as ranges may assume any particular value within the stated range, in some embodiments, to 1 / 10 of the unit of the lower limit of the range, unless the context clearly dictates otherwise. For the sake of brevity, each range value is not specifically detailed herein, but it will be understood that each of these values is provided herein and may be specifically claimed or disclaimed. It should also be understood that unless otherwise indicated or clear from the context and / or understanding of one of ordinary skill in the art, values expressed as ranges may assume any subrange within the given range, with the endpoints of the subranges being expressed to the same degree of precision as 1 / 10 of the unit of the lower limit of the range.
[0247] In addition, it is to be understood that any particular embodiment of the present invention may be explicitly excluded from any one or more of the claims. Where a range is given, any value within that range may be explicitly excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and / or methods described herein may be excluded from any one or more claims. For the sake of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects are excluded are not explicitly described herein.
Claims
1. A gRNA comprising a targeting domain, wherein the targeting domain comprises a sequence described in Tables 1-8.
2. 1. A gRNA comprising a targeting domain, wherein the targeting domain comprises the sequence of any one of SEQ ID NOs: 59-76, 125-148, 161-166, 179, 180, 183, 184, 186, 189, 192, 195, 201, 204, 207, 210, 213, 216, 219, 222, 225, 228, 231, 234, 237, 249, 243, 246, 249, 252, 254-257, 268, 271, 274, 277, 280, 283, 286, 289, 291, 294, 297, 300, 303, 306, 309, 312, 315, 317, and 219.
3. 3. The gRNA of claim 1, wherein the gRNA comprises a first complementary domain, a binding domain, a second complementary domain that is complementary to the first complementary domain, and a proximal domain.
4. The gRNA of any one of claims 1 to 3, wherein the gRNA is a single guide RNA (sgRNA).
5. The gRNA of any one of claims 1 to 4, wherein the gRNA comprises one or more nucleotide residues that are chemically modified.
6. The gRNA of any one of claims 1 to 5, wherein the gRNA comprises one or more nucleotide residues comprising a 2'O-methyl moiety.
7. The gRNA of any one of claims 1 to 6, wherein the gRNA comprises one or more nucleotide residues that include phosphorothioates.
8. The gRNA of any one of claims 1 to 7, wherein the gRNA comprises one or more nucleotide residues comprising a thioPACE moiety.
9. 1. A method for producing a genetically engineered cell, comprising: a. providing cells; b. Contacting the cell with (i) a gRNA according to any one of claims 1 to 8, or a gRNA targeting a targeting domain targeted by the gRNA of any one of claims 1 to 8, and (ii) an RNA-guided nuclease that binds to the gRNA, thereby forming a ribonucleoprotein (RNP) complex under conditions suitable for the gRNA of (i) to form and / or maintain a ribonucleoprotein (RNP) complex with the RNA-guided nuclease of (ii), and for the RNP complex to bind to a target domain in the genome of the cell.
10. 10. The method of claim 9, wherein the RNA-guided nuclease is a CRISPR / Cas nuclease.
11. 11. The method of claim 10, wherein the CRISPR / Cas nuclease is a Cas9 nuclease.
12. 11. The method of claim 10, wherein the CRISPR / Cas nuclease is an spCas nuclease.
13. 11. The method of claim 10, wherein the Cas nuclease is a saCas nuclease.
14. 11. The method of claim 10, wherein the CRISPR / Cas nuclease is a Cpf1 nuclease.
15. 15. The method of any one of claims 1 to 14, wherein the CRISPR / Cas nuclease is a base editor.
16. 16. The method of claim 15, wherein the CRISPR / Cas nuclease is a cytosine base editor or an adenine base editor.
17. 17. The method of any one of claims 9 to 16, wherein said contacting comprises introducing (i) and (ii) into said cell in the form of a preformed ribonucleoprotein (RNP) complex.
18. 17. The method of any one of claims 9 to 16, wherein said contacting comprises introducing (i) and / or (ii) into said cell in the form of a nucleic acid encoding (i) the gRNA and / or (ii) the RNA-guided nuclease.
19. 19. The method of any one of claims 9 to 16 or 18, wherein the nucleic acid encoding (i) the gRNA and / or (ii) the RNA-guided nuclease is RNA, preferably mRNA or an mRNA analogue.
20. The method of any one of claims 9 to 17, wherein the ribonucleoprotein complex is introduced into the cell via electroporation.
21. The method of any one of claims 9 to 20, wherein the cells are hematopoietic cells.
22. The method of any one of claims 9 to 21, wherein the cells are hematopoietic stem cells.
23. The method of any one of claims 9 to 22, wherein the cells are hematopoietic progenitor cells.
24. The method of any one of claims 9 to 20, wherein the cell is an immune effector cell.
25. 25. The method of any one of claims 9 to 20 or 24, wherein the cells are lymphocytes.
26. 26. The method of any one of claims 9 to 20, 24, or 25, wherein the cell is a T lymphocyte.
27. A genetically engineered cell obtained by the method of any one of claims 9 to 26.
28. 28. A cell population comprising the genetically engineered cells of claim 27.
29. 1. A cell population comprising genetically engineered cells, wherein the genetically engineered cells comprise a genomic modification consisting of an insertion or deletion immediately proximal to a site cleaved by an RNA-guided nuclease when the genetically engineered cells are bound to a gRNA comprising a targeting domain described in any of Tables 1-8.
30. 30. The cell population of claim 29, wherein the genomic modification is an insertion or deletion generated by a non-homologous end joining (NHEJ) event.
31. 30. The cell population of claim 29, wherein the genomic modification is an insertion or deletion generated by a homology-directed repair (HDR) event.
32. 32. The cell population of any one of claims 29 to 31, wherein the genomic modification results in a loss of function of EMR2 in genetically engineered cells harboring such genomic modification.
33. 33. The cell population of any one of claims 29 to 32, wherein the genomic modification results in a reduction in expression of EMR2 to less than 25%, less than 20%, less than 10%, less than 5%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, or less than 0.001% compared to the expression level of EMR2 in a wild-type cell of the same cell type that does not lack the EMR2 genomic modification.
34. 34. The cell population of any one of claims 29 to 33, wherein the genetically engineered cells are hematopoietic stem or progenitor cells.
35. The cell population of any one of claims 29 to 33, wherein the genetically engineered cells are immune effector cells.
36. 36. The cell population of any one of claims 29 to 33 or 35, wherein the genetically engineered cells are T lymphocytes.
37. 37. The cell population of any one of claims 35 and 36, wherein the immune effector cells express a chimeric antigen receptor (CAR).
38. The cell population of claim 37, wherein the CAR targets EMR2.
39. 35. The cell population of any one of claims 28 to 34, characterized by the ability to engraft EMR2-edited hematopoietic stem cells into the bone marrow of a recipient and generate differentiated progeny of all blood lineage cell types in the recipient.
40. 40. The cell population of any one of claims 28 to 34 or 39, characterized by the ability to engraft EMR2-edited hematopoietic stem cells into the bone marrow of a recipient with an efficiency of at least 50%.
41. 41. The cell population of any one of claims 28 to 34, 39 or 40, characterized by the ability to engraft EMR2-edited hematopoietic stem cells into the bone marrow of a recipient with an efficiency of at least 60%.
42. 42. The cell population of any one of claims 28 to 34 or 39 to 41, characterized by the ability to engraft EMR2-edited hematopoietic stem cells into the bone marrow of a recipient with an efficiency of at least 70%.
43. 43. The cell population of any one of claims 28 to 34 or 39 to 42, characterized by the ability to engraft EMR2-edited hematopoietic stem cells into the bone marrow of a recipient with an efficiency of at least 80%.
44. 44. The cell population of any one of claims 28 to 34 or 39 to 43, characterized by the ability to engraft EMR2-edited hematopoietic stem cells into the bone marrow of a recipient with at least 90% efficiency.
45. The cell population of any one of claims 28 to 34 or 39 to 44, wherein the cell population comprises EMR2-edited hematopoietic stem cells characterized by a differentiation potential that is equivalent to that of unedited hematopoietic stem cells.
46. 46. A method comprising administering the genetically engineered cells of claim 27 or the cell population of any one of claims 28 to 45 to a subject in need thereof.
47. 47. The method of claim 46, wherein the subject has or has been diagnosed with a hematopoietic malignancy.
48. 48. The method of claim 46 or 47, further comprising administering to the subject an effective amount of an agent that targets EMR2, wherein the agent comprises an antigen-binding fragment that binds to EMR2.
